Type 2 diabetes mellitus (DM) is caused by hyperglycemia and metabolic alterations due to abnormalities in insulin secretion or insulin action, or both. To achieve desired glycemic targets, different antihyperglycemic drugs are used alone or in combination with other agents, including insulin. First-line options for diabetes treatment are weight loss, lifestyle modification, and metformin. The American Diabetes Association and the European Association for the Study of Diabetes recommend a patient-specific treatment approach to enhance glycemic control while avoiding weight gain and hypoglycemia.¹ This review will focus on the newer oral agents and injectable noninsulin agents that are used to achieve glycemic control. Table 1 lists the noninsulin drugs approved since 2005.

INCRETIN-BASED THERAPIES

The incretins are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which are secreted by the gastrointestinal (GI) tract in response to food intake. Both GLP-1 and GIP stimulate beta cells of the pancreas, which contribute 60% of the insulin secretion after a meal. Type 2 DM is associated with decreased secretion of GLP-1 and lowered responsiveness to GIP. Benefits of the incretin hormones on glycemic control include enhanced satiety, decreased GI motility, increased glucose-dependent insulin secretion, reduced glucagon secretion, and decreased hepatic glucose release.² Two incretin-based drug classes are used to treat patients with type 2 DM—oral dipeptidyl peptidase-4 (DPP-4) inhibitors and GLP-1 receptor agonists.

DPP-4 inhibitors

The oral DPP-4 inhibitors block the degradation of the enzyme DPP-4 active site and thus increase the GLP-1 and GIP concentrations by two to three times. Their primary effectiveness centers on controlling insulin and glucagon secretion without increasing weight.

Four DPP-4 inhibitors are approved by the US Food and Drug Administration (FDA) in once-daily oral formulations: sitagliptin, saxagliptin, linagliptin, and alogliptin. Another DPP-4 inhibitor, vildagliptin, is not licensed in the United States but is approved for use in Europe and Japan.³ Another DPP-4 inhibitor, teneligliptin, is also marketed in Japan.

The DPP-4 inhibitors are indicated for use as monotherapy or in combination with other agents such as metformin, sulfonylureas, thiazolidinediones, and insulin. Generally, DPP-4 inhibitors do not cause hypoglycemia when used as monotherapy.¹ When adding a DPP-4 inhibitor to a sulfonylurea or insulin, it is recommended to decrease the sulfonylurea or insulin dose to reduce the risk of hypoglycemia. The potential of these agents to lower the hemoglobin A1c (HbA1c) when used as monotherapy and in combination with metformin, sulfonylureas, or thiazolidine­diones is 0.3% to 0.71%.⁴

The DPP-4 inhibitors are not known to cause adverse GI effects. Sitagliptin, alogliptin, vildagliptin, and saxagliptin need dosing adjustments for renal insufficiency; however, linagliptin is not renally eliminated and does not require dosing adjustment. Common adverse events (> 5%) are nasopharyngitis, upper-respiratory infection, and headache. Sitagliptin and saxagliptin have been associated with urinary tract infection. Sitagliptin also has been associated with more extremity pain, back pain, and osteoarthritis.⁴

The DPP-4 inhibitors are primarily excreted by the renal or fecal route and, therefore, have few drug interactions. All DPP-4 inhibitors are partially metabolized through cytochrome P450 enzymes, except saxagliptin.⁴ Their pharmacokinetic profiles are shown on Table 2.

In keeping with the FDA guidelines, sitagliptin, saxagliptin, linagliptin, and alogliptin have been evaluated for cardiovascular (CV) outcomes. The SAVOR-TIMI 53 clinical trial (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients With Diabetes Mellitus–Thrombolysis in Myocardial Infarction 53) was a 2-year CV safety and efficacy trial.⁵ This trial demonstrated no statistically significant difference in the primary end point as a composite of CV death, myocardial infarction (MI), and ischemic stroke. Additionally, the secondary end points, including hospitalization for unstable angina, coronary revascularization, and heart failure, also did not show significant difference. However, based on a subgroup analysis, there was a statistically significant increase in patients in the saxagliptin group vs the placebo group who were hospitalized for heart failure.

A 2-year trial comparing linagliptin with glimepiride, a second-generation sulfonylurea, showed significantly fewer CV events with linagliptin.⁶ This trial found a relative risk reduction of 54% in the end points of CV death, nonfatal MI or stroke, and unstable angina during hospitalization.^4,6 Another trial reviewed the incidence of CV events (CV death, nonfatal MI, and nonfatal stroke) in patients treated with alogliptin, placebo, or comparator antihyperglycemic drugs and found no increased incidence of major adverse CV events vs comparator therapies.⁷

The recently published TECOS (Trial Evaluating Cardiovascular Outcomes With Sitagliptin), reported no increase in major atherosclerotic CV events, no difference in all-cause mortality, and no difference in heart failure for hospitalization or other adverse events in patients with type 2 DM.⁸ Other clinical trials such as the CAROLINA study (linagliptin compared with glimepiride),⁹ the EXAMINE study (alogliptin),¹⁰ and the CARMALINA study (linagliptin)¹¹ are also reviewing the CV safety of DPP-4 inhibitors in the United States.

Concern has been raised about the association between incretin-based therapies and adverse pancreatic effects. CV outcomes trials using saxagliptin and alogliptin found similar rates of pancreatitis and fewer pancreatic cancer cases in comparison with placebo.^5,7,10 TECOS demonstrated that with sitagliptin, acute pancreatitis occurred more in the sitagliptin group, but there was no statistical significance reported. However, pancreatic cancer occurred more in the placebo group, although the difference was not statistically significant.⁸ Neither the FDA nor the European Medicines Agency (EMA) has reached a firm conclusion about the possible association between incretin-based therapies and pancreatitis or pancreatic cancer.¹²

GLP-1 agonists

The GLP-1 drugs mimic the action of native GLP-1. Several GLP-1 agents are available in the United States, and several more are in development.^11,13 The drug class is divided into three groups:

• Short-acting (4–6 hours): exenatide, lixisenatide
• Intermediate-acting (24 hours): liraglutide
• Long-acting (7 days): exenatide extended-release (ER), dulaglutide, and albiglutide (semaglutide is in phase 3 study).

The GLP-1 receptor agonists heighten glucose homeostasis by the following mechanisms of action: stimulate insulin secretion, suppress glucagon secretion, directly and indirectly inhibit endogenous glucose production, promote satiety, heighten insulin sensitivity due to weight loss, and slow gastric emptying time. Table 3 lists dosing and pharmacokinetic profiles for GLP-1 agonists. When GLP-1 agonists are used as monotherapy, the HbA1c is reduced by 0.7% to 1.51%.¹³ When GLP-1 agonists are used in combination with metformin, sulfonylureas, thiazolidinediones, or as three-drug therapy with other oral antidiabetic medications, the HbA1c is lowered by 0.4% to 1.9%.^13–17

A notable advantage of GLP-1 agonists is their effect on weight loss separate from GI side effects. Weight reductions of 0.2 to 3.6 kg in 26 weeks have been seen with the exenatide formulations, liraglutide, albiglutide, and dulaglutide.^13,18 Liraglutide has demonstrated a greater weight reduction than exenatide, exenatide ER, or albiglutide.^13,16,17 There were similar weight reductions of 1.5 kg in 26 weeks in a comparator trial involving liraglutide and dulaglutide (3.6 vs 2.9 kg).¹⁹

Common adverse effects of the GLP-1 agonists are nausea (8% to 44%), diarrhea (6% to 20%), and vomiting (4% to 18%), which may occur initially and diminish with continued use.^13,14 There have been more GI side effects with liraglutide than with exenatide ER or albiglutide.²⁰ Increased rates of injection site reactions, such as transient small nodule formations, were seen with exenatide ER (5.4% to 17.6%) and albiglutide, the once-weekly GLP-1 agonist therapies, vs exenatide, liraglutide, and insulin glargine.^13,14 Dulaglutide, another once-weekly GLP-1 agonist, does not have this finding; however, there is enhanced patient satisfaction with the once-weekly preparations in comparison with the twice-daily preparations.^14,16 Patients who received albiglutide have noted hypersensitivity reactions such as pruritus, rash, and dyspnea (10% to 18%).¹³ Hypoglycemia is not seen with the GLP-1 agonists, unless they are used in conjunction with a sulfonylurea or insulin.

Exenatide and exenatide ER are excreted by the renal route; therefore, it is not recommended to use these agonists in patients with renal impairment or end-stage renal disease (creatinine clearance [CrCl] < 30 mL/min). Liraglutide is not excreted by the renal route; however, it should be used with caution in patients with renal impairment.²¹ No renal dose adjustment is required when using albiglutide or dulaglutide.²¹

Clinical trials have demonstrated the short-term CV outcomes of GLP-1 agonists. The CV benefits include a decrease in blood pressure, reduction of lipid levels, enhanced endothelial function, and improved myocardial function.¹³ One meta-analysis reported a tendency for lowering the rate of major CV events, stroke, MI, CV mortality, and all-cause mortality.²² Several ongoing trials are evaluating the safety of GLP-1 agonists and CV safety: LEADER (liraglutide), EXSCEL (exenatide LR), ELIXA (lixisenatide), SUSTAIN 6 (semaglutide), and REWIND (dulaglutide).¹¹

The GLP-1 agonists have been linked to an increased incidence of thyroid cancer. There was a potential increased risk of thyroid cancer in preclinical rodent studies involving liraglutide and exenatide ER, but this risk was not demonstrated for the exenatide twice-daily preparation.¹³ The FDA noted that the findings from rodent studies, which demonstrated a possible heightened risk for thyroid cancer, should not be conveyed to the outcomes for humans. Nevertheless, when liraglutide was approved in January 2010, the FDA issued a boxed warning about the risk of thyroid C-cell hyperplasia. The package inserts list a thyroid carcinoma risk for exenatide ER, liraglutide, albiglutide, and dulaglutide in those patients with a personal or family history of medullary thyroid cancer.

There is controversy about the incidence of pancreatitis and pancreatic cancer with the use of the incretin-based therapies. Published studies and case reports seem to support speculation that there is an increased incidence of acute pancreatitis associated with type 2 DM.²¹ The FDA and the EMA have independently reviewed postmarketing reports about pancreatitis and pancreatic cancer among more than 28,000 patients who received some form of incretin-based therapy.¹² They independently agreed that a causal association between incretin-based drugs and pancreatitis or pancreatic cancer is inconsistent with the current data.¹² At this time, there is no final conclusion about a causal relationship between the use of incretin-based drugs and possible pancreatitis and pancreatic cancer.

SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS

In 2013, canagliflozin became the first sodium-glucose cotransporter-2 (SGLT-2) inhibitor to be FDA-approved for treating patients with type 2 DM, followed in 2014 by dapagliflozin and empagliflozin. Several other drugs in this class are available outside the US or are currently undergoing clinical development, including ipragliflozin, luseogliflozin, tofogliflozin, and ertugliflozin. Currently, no SGLT-2 inhibitors are FDA-approved for type 1 DM, although they have been used off-label and in trials in this patient population.

These drugs work by targeting the SGLT-2 protein in the kidney. In healthy individuals, 99% of filtered glucose is reabsorbed by the kidney with a filtered load of approximately 180 g/day.²³ Glucosuria occurs with glucose concentrations above this threshold. In patients with type 2 DM, this threshold and the ability to reabsorb glucose is increased, contributing to hyperglycemia.²⁴ Located in the proximal tubule, the SGLT-2 protein is responsible for 80% to 90% of glucose reabsorption, with SGLT-1 responsible for the other 10% to 20%.²⁵ Inhibition of SGLT-2 reduces the renal threshold for glucose, thus leading to glucosuria and reduction in serum glucose levels.²⁴ Table 4 lists dosing regimens, HbA1c effects, and side-effect profiles for the SGLT-2 inhibitors.

As a monotherapy, SGLT-2 inhibitors significantly reduce HbA1c levels by 0.4% to 1.1% when compared with placebo.^26–28 Reductions may be more significant in patients with HbA1c levels greater than 8.5%, and even more so in patients with HbA1c levels above 10%.²⁹ When compared with other therapeutic options for type 2 DM, SGLT-2 inhibitors have efficacy similar to metformin, sitagliptin, and glipizide; however, some studies have shown superiority to glimepiride and sitagliptin at reducing HbA1c, depending on the dose and duration of treatment.^26,27

The SGLT-2 inhibitors do not rely on insulin activity, allowing for their use at any stage of type 2 DM and in combination with other therapies, including insulin. As an add-on medication, SGLT-2 inhibitors reduce HbA1c by 0.5% to 0.7%.^27,28 Given that the mechanism of action depends on the filtered load of glucose, they are less effective in patients with a reduced glomerular filtration rate (GFR).

The SGLT-2 inhibitors have bene­fits beyond that of glycemic control. Studies report weight loss of 1 to 3 kg, which is maintained up to 104 weeks.^27–31 Sustained weight loss is secondary to glucosuria, which amounts to a caloric loss of 200 to 300 kcal/day.³⁰ Also, SGLT-2 inhibitors lead to modest reductions in systolic and diastolic blood pressure of approximately 3 to 6 mm Hg and 1 to 2 mm Hg, respectively, due to their diuretic effect.^27,31 The risk of hypoglycemia is low—similar to that of metformin and DPP-4 inhibitors—and only slightly higher than placebo when used as monotherapy.^26,31 When added to sulfonylureas or insulin, however, the risk of hypoglycemia is increased.^26,29

Meta-analyses of SGLT-2 inhibitors showed rates of death and other serious adverse effects were no different than placebo.^26,27 A 2015 study on the CV safety of empagliflozin showed lower rates of CV death (38% relative risk [RR] reduction), lower rates of hospitalization due to heart failure (35% RR reduction), and lower rates of all-cause mortality (32% RR reduction) when compared with placebo, with no difference in nonfatal stroke and MI.³² CV safety trials for dapagliflozin and canagliflozin are ongoing, although some trials have shown an increased incidence in CV events in the first 30 days of treatment with canagliflozin.⁴

Common side effects include genital infections, such as vaginitis and balanitis, as well as urinary tract infections. In a 2013 meta-analysis,²⁷ genital infections carried an odds ratio of 3.5 for SGLT-2 inhibitors compared with placebo, while urinary tract infections carried a 1.34 odds ratio. The increased risk of infection is thought to be secondary to glucosuria combined with immune dysfunction and altered glycosylation uroepithelium cells.³⁰

During clinical trials, more cases of bladder cancer were diagnosed in patients on dapagliflozin than on placebo, leading to a delay in FDA approval. No causal relationship was established, but dapagliflozin is not recommended in patients with active bladder cancer.³⁰

Treatment with SGLT-2 inhibitors can lead to a decrease in GFR, likely secondary to the diuretic effect. In patients with GFR greater than 60 mL/min, this decrease is transient. In patients with GFR below 60 mL/min (moderate renal impairment) who were treated with dapagliflozin, GFR did not quite return to baseline, and they did not show an improvement in HbA1c relative to placebo.³³ Canagliflozin at a dose of 300 mg/day caused renal-related adverse events with GFR 45 to 60 mL/min, but a lower dose of 100 mg/day did not.²⁷ A decrease in GFR also occurred in patients with chronic kidney disease treated with empagliflozin, which returned to baseline after discontinuing the drug.³¹ Despite these findings, renal function stabilizes in patients on SGLT-2 inhibitors over time, whereas it continues to decrease with placebo, suggesting there may be a renal protective effect.³⁰ Their diuretic effect can also lead to volume depletion in patients at risk such as elderly patients or those already taking diuretics.³¹

Some studies have shown mild increases in low-density lipoprotein (LDL) and high-density lipoprotein (HDL) levels with no change in triglycerides, though long-term effects of this are unknown.³¹

There are case reports of euglycemic diabetic ketoacidosis occurring in patients with type 1 DM and type 2 DM treated with SGLT-2 inhibitors, which led the FDA in May 2015 to issue a warning that SGLT-2 inhibitors may increase the risk of ketoacidosis.³⁴ There are several possible mechanisms for this increased risk. The SGLT-2 inhibitors may decrease renal clearance of ketones, stimulate glucagon secretion leading to hepatic ketogenesis, or suppress glucose-mediated insulin secretion leading practitioners to decrease insulin doses thus resulting in increased ketone production via lipolysis.³⁴ More studies are needed, but patients and healthcare providers should be aware of potential euglycemic ketoacidosis associated with SGLT-2-inhibitors, as the lack of hyperglycemia can delay the diagnosis.

BILE ACID SEQUESTRANTS

Bile acid sequestrants have been used for years in hyperlipidemia to reduce LDL concentration; however, colesevelam is the only drug in this class approved (2009) for treating type 2 DM, after studies showed colesevelam improves glycemic control.^35–37 Though several possibilities have been proposed, the precise mechanism of action for lowering blood glucose levels is unknown.³⁵ Colesevelam is not absorbed systemically and does not affect endogenous insulin levels.⁴ Table 4 lists dosing regimens, HbA1c effects, and side-effect profiles for colesevelam.

As monotherapy, studies have shown varying effectiveness in reducing HbA1c relative to placebo ranging from no statistical difference to 0.54% reduction.^36,37 As an add-on to other diabetic medications, a Cochrane review of six randomized controlled trials showed a decrease in HbA1c by 0.3% to 0.5% and decrease in fasting glucose of 15 mg/dL.³⁷ Additional benefits of colesevelam include low risk for hypoglycemia, weight neutrality, and reduction in LDL.⁴ No serious adverse events or deaths have been associated with colesevelam, including CV events; however, more trials on macrovascular outcomes are needed to clarify its side-effect profile.³⁵

Common side effects include constipation, flatulence, and dyspepsia.³⁵ Colesevelam has shown a statistically significant increase in triglycerides, so its use in patients with triglycerides above 500 mg/dL or with hypertriglyceridemia-induced pancreatitis is contraindicated.⁴ Caution should be used prior to starting treatment in patients with triglyceride levels above 200 mg/dL.³⁵ Colesevelam is contraindicated in patients with a history of small-bowel obstruction, and caution is recommended in patients with decreased gastric motility. This drug may reduce absorption of fat-soluble vitamins and some medications.⁴

Although further research into the long-term effects of colesevelam is needed, its relatively good safety profile makes it a reasonable choice in diabetic patients with hyperlipidemia not controlled with statins.

DOPAMINE-RECEPTOR AGONIST

Bromocriptine, a dopamine-receptor agonist, was FDA-approved for the treatment of Parkinson disease, hyperprolactinemia, and acromegaly in the 1970s. In 2009, a quick-release formulation of bromocriptine (bromocriptine QR) was approved for treatment of type 2 DM. Table 4 lists dosing regimens, HbA1c effects, and side-effect profiles for bromocriptine.

The precise mechanism of action is unclear, but an American Association of Clinical Endocrinologists expert panel recommendation suggests that it may lower glucose levels by improving hypothalamic-mediated, postprandial insulin sensitivity via increasing morning dopaminergic activity (decreased in patients with type 2 DM) and by reducing hypothalamic adrenergic tone.³⁸ It is not currently recommended as monotherapy, although a study of 154 patients showed monotherapy reduced HbA1c by 0.55%.³⁹ When added to other diabetic medications, it reduced HbA1c by 0.4% to 0.7%.^4,38

Bromocriptine QR is weight neutral and carries a low risk of hypoglycemia.⁴ A safety trial with 3,095 patients showed fewer adverse CV events in patients treated with bromocriptine QR compared with placebo, which may be secondary to reduced sympathetic tone or to reduced systemic inflammation.⁴⁰ Some studies have shown reductions in blood pressure, free fatty acid levels, and triglycerides, with no change in LDL or HDL.³⁸

Common side effects include nausea, headache, dizziness, diarrhea, and fatigue. Administration is recommended with food to reduce GI side effects. It is contraindicated in women who are nursing and those with syncopal migraines. Furthermore, it may be prudent to avoid this medication in patients with a history of psychosis, those currently treated with dopamine agonists or antagonists, or those at risk for hypotension.⁴

CONCLUSION

The pathophysiology of type 2 DM involves at least seven organs and tissues—the brain, liver, pancreas, intestines, kidneys, fat, and muscle—and no single medication addresses all seven of them. Most patients require more than one medication to adequately treat their diabetes, making availability and development of drugs with unique and complementary mechanisms of action of paramount importance. The medications described here—DPP-4 inhibitors, GLP-1 agonists, SGLT-2 inhibitors, colesevelam, and bromocriptine QR—provide therapeutic options with novel mechanisms of action, all while avoiding weight gain and providing a low risk of hypoglycemia. While not appropriate for every patient, these medications give healthcare providers additional options to individualize treatment and optimize care for patients.
 

Acknowledgments. The authors gratefully thank Julie Benke-Bennett for assistance with manuscript formatting and transcription. The contents of this article do not represent the views of the Department of Veterans Affairs or the United States Government.

Type 2 diabetes mellitus (DM) is caused by hyperglycemia and metabolic alterations due to abnormalities in insulin secretion or insulin action, or both. To achieve desired glycemic targets, different antihyperglycemic drugs are used alone or in combination with other agents, including insulin. First-line options for diabetes treatment are weight loss, lifestyle modification, and metformin. The American Diabetes Association and the European Association for the Study of Diabetes recommend a patient-specific treatment approach to enhance glycemic control while avoiding weight gain and hypoglycemia.¹ This review will focus on the newer oral agents and injectable noninsulin agents that are used to achieve glycemic control. Table 1 lists the noninsulin drugs approved since 2005.

INCRETIN-BASED THERAPIES

The incretins are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which are secreted by the gastrointestinal (GI) tract in response to food intake. Both GLP-1 and GIP stimulate beta cells of the pancreas, which contribute 60% of the insulin secretion after a meal. Type 2 DM is associated with decreased secretion of GLP-1 and lowered responsiveness to GIP. Benefits of the incretin hormones on glycemic control include enhanced satiety, decreased GI motility, increased glucose-dependent insulin secretion, reduced glucagon secretion, and decreased hepatic glucose release.² Two incretin-based drug classes are used to treat patients with type 2 DM—oral dipeptidyl peptidase-4 (DPP-4) inhibitors and GLP-1 receptor agonists.

DPP-4 inhibitors

The oral DPP-4 inhibitors block the degradation of the enzyme DPP-4 active site and thus increase the GLP-1 and GIP concentrations by two to three times. Their primary effectiveness centers on controlling insulin and glucagon secretion without increasing weight.

Four DPP-4 inhibitors are approved by the US Food and Drug Administration (FDA) in once-daily oral formulations: sitagliptin, saxagliptin, linagliptin, and alogliptin. Another DPP-4 inhibitor, vildagliptin, is not licensed in the United States but is approved for use in Europe and Japan.³ Another DPP-4 inhibitor, teneligliptin, is also marketed in Japan.

The DPP-4 inhibitors are indicated for use as monotherapy or in combination with other agents such as metformin, sulfonylureas, thiazolidinediones, and insulin. Generally, DPP-4 inhibitors do not cause hypoglycemia when used as monotherapy.¹ When adding a DPP-4 inhibitor to a sulfonylurea or insulin, it is recommended to decrease the sulfonylurea or insulin dose to reduce the risk of hypoglycemia. The potential of these agents to lower the hemoglobin A1c (HbA1c) when used as monotherapy and in combination with metformin, sulfonylureas, or thiazolidine­diones is 0.3% to 0.71%.⁴

The DPP-4 inhibitors are not known to cause adverse GI effects. Sitagliptin, alogliptin, vildagliptin, and saxagliptin need dosing adjustments for renal insufficiency; however, linagliptin is not renally eliminated and does not require dosing adjustment. Common adverse events (> 5%) are nasopharyngitis, upper-respiratory infection, and headache. Sitagliptin and saxagliptin have been associated with urinary tract infection. Sitagliptin also has been associated with more extremity pain, back pain, and osteoarthritis.⁴

The DPP-4 inhibitors are primarily excreted by the renal or fecal route and, therefore, have few drug interactions. All DPP-4 inhibitors are partially metabolized through cytochrome P450 enzymes, except saxagliptin.⁴ Their pharmacokinetic profiles are shown on Table 2.

In keeping with the FDA guidelines, sitagliptin, saxagliptin, linagliptin, and alogliptin have been evaluated for cardiovascular (CV) outcomes. The SAVOR-TIMI 53 clinical trial (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients With Diabetes Mellitus–Thrombolysis in Myocardial Infarction 53) was a 2-year CV safety and efficacy trial.⁵ This trial demonstrated no statistically significant difference in the primary end point as a composite of CV death, myocardial infarction (MI), and ischemic stroke. Additionally, the secondary end points, including hospitalization for unstable angina, coronary revascularization, and heart failure, also did not show significant difference. However, based on a subgroup analysis, there was a statistically significant increase in patients in the saxagliptin group vs the placebo group who were hospitalized for heart failure.

A 2-year trial comparing linagliptin with glimepiride, a second-generation sulfonylurea, showed significantly fewer CV events with linagliptin.⁶ This trial found a relative risk reduction of 54% in the end points of CV death, nonfatal MI or stroke, and unstable angina during hospitalization.^4,6 Another trial reviewed the incidence of CV events (CV death, nonfatal MI, and nonfatal stroke) in patients treated with alogliptin, placebo, or comparator antihyperglycemic drugs and found no increased incidence of major adverse CV events vs comparator therapies.⁷

The recently published TECOS (Trial Evaluating Cardiovascular Outcomes With Sitagliptin), reported no increase in major atherosclerotic CV events, no difference in all-cause mortality, and no difference in heart failure for hospitalization or other adverse events in patients with type 2 DM.⁸ Other clinical trials such as the CAROLINA study (linagliptin compared with glimepiride),⁹ the EXAMINE study (alogliptin),¹⁰ and the CARMALINA study (linagliptin)¹¹ are also reviewing the CV safety of DPP-4 inhibitors in the United States.

Concern has been raised about the association between incretin-based therapies and adverse pancreatic effects. CV outcomes trials using saxagliptin and alogliptin found similar rates of pancreatitis and fewer pancreatic cancer cases in comparison with placebo.^5,7,10 TECOS demonstrated that with sitagliptin, acute pancreatitis occurred more in the sitagliptin group, but there was no statistical significance reported. However, pancreatic cancer occurred more in the placebo group, although the difference was not statistically significant.⁸ Neither the FDA nor the European Medicines Agency (EMA) has reached a firm conclusion about the possible association between incretin-based therapies and pancreatitis or pancreatic cancer.¹²

GLP-1 agonists

The GLP-1 drugs mimic the action of native GLP-1. Several GLP-1 agents are available in the United States, and several more are in development.^11,13 The drug class is divided into three groups:

• Short-acting (4–6 hours): exenatide, lixisenatide
• Intermediate-acting (24 hours): liraglutide
• Long-acting (7 days): exenatide extended-release (ER), dulaglutide, and albiglutide (semaglutide is in phase 3 study).

The GLP-1 receptor agonists heighten glucose homeostasis by the following mechanisms of action: stimulate insulin secretion, suppress glucagon secretion, directly and indirectly inhibit endogenous glucose production, promote satiety, heighten insulin sensitivity due to weight loss, and slow gastric emptying time. Table 3 lists dosing and pharmacokinetic profiles for GLP-1 agonists. When GLP-1 agonists are used as monotherapy, the HbA1c is reduced by 0.7% to 1.51%.¹³ When GLP-1 agonists are used in combination with metformin, sulfonylureas, thiazolidinediones, or as three-drug therapy with other oral antidiabetic medications, the HbA1c is lowered by 0.4% to 1.9%.^13–17

A notable advantage of GLP-1 agonists is their effect on weight loss separate from GI side effects. Weight reductions of 0.2 to 3.6 kg in 26 weeks have been seen with the exenatide formulations, liraglutide, albiglutide, and dulaglutide.^13,18 Liraglutide has demonstrated a greater weight reduction than exenatide, exenatide ER, or albiglutide.^13,16,17 There were similar weight reductions of 1.5 kg in 26 weeks in a comparator trial involving liraglutide and dulaglutide (3.6 vs 2.9 kg).¹⁹

Common adverse effects of the GLP-1 agonists are nausea (8% to 44%), diarrhea (6% to 20%), and vomiting (4% to 18%), which may occur initially and diminish with continued use.^13,14 There have been more GI side effects with liraglutide than with exenatide ER or albiglutide.²⁰ Increased rates of injection site reactions, such as transient small nodule formations, were seen with exenatide ER (5.4% to 17.6%) and albiglutide, the once-weekly GLP-1 agonist therapies, vs exenatide, liraglutide, and insulin glargine.^13,14 Dulaglutide, another once-weekly GLP-1 agonist, does not have this finding; however, there is enhanced patient satisfaction with the once-weekly preparations in comparison with the twice-daily preparations.^14,16 Patients who received albiglutide have noted hypersensitivity reactions such as pruritus, rash, and dyspnea (10% to 18%).¹³ Hypoglycemia is not seen with the GLP-1 agonists, unless they are used in conjunction with a sulfonylurea or insulin.

Exenatide and exenatide ER are excreted by the renal route; therefore, it is not recommended to use these agonists in patients with renal impairment or end-stage renal disease (creatinine clearance [CrCl] < 30 mL/min). Liraglutide is not excreted by the renal route; however, it should be used with caution in patients with renal impairment.²¹ No renal dose adjustment is required when using albiglutide or dulaglutide.²¹

Clinical trials have demonstrated the short-term CV outcomes of GLP-1 agonists. The CV benefits include a decrease in blood pressure, reduction of lipid levels, enhanced endothelial function, and improved myocardial function.¹³ One meta-analysis reported a tendency for lowering the rate of major CV events, stroke, MI, CV mortality, and all-cause mortality.²² Several ongoing trials are evaluating the safety of GLP-1 agonists and CV safety: LEADER (liraglutide), EXSCEL (exenatide LR), ELIXA (lixisenatide), SUSTAIN 6 (semaglutide), and REWIND (dulaglutide).¹¹

The GLP-1 agonists have been linked to an increased incidence of thyroid cancer. There was a potential increased risk of thyroid cancer in preclinical rodent studies involving liraglutide and exenatide ER, but this risk was not demonstrated for the exenatide twice-daily preparation.¹³ The FDA noted that the findings from rodent studies, which demonstrated a possible heightened risk for thyroid cancer, should not be conveyed to the outcomes for humans. Nevertheless, when liraglutide was approved in January 2010, the FDA issued a boxed warning about the risk of thyroid C-cell hyperplasia. The package inserts list a thyroid carcinoma risk for exenatide ER, liraglutide, albiglutide, and dulaglutide in those patients with a personal or family history of medullary thyroid cancer.

There is controversy about the incidence of pancreatitis and pancreatic cancer with the use of the incretin-based therapies. Published studies and case reports seem to support speculation that there is an increased incidence of acute pancreatitis associated with type 2 DM.²¹ The FDA and the EMA have independently reviewed postmarketing reports about pancreatitis and pancreatic cancer among more than 28,000 patients who received some form of incretin-based therapy.¹² They independently agreed that a causal association between incretin-based drugs and pancreatitis or pancreatic cancer is inconsistent with the current data.¹² At this time, there is no final conclusion about a causal relationship between the use of incretin-based drugs and possible pancreatitis and pancreatic cancer.

SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS

In 2013, canagliflozin became the first sodium-glucose cotransporter-2 (SGLT-2) inhibitor to be FDA-approved for treating patients with type 2 DM, followed in 2014 by dapagliflozin and empagliflozin. Several other drugs in this class are available outside the US or are currently undergoing clinical development, including ipragliflozin, luseogliflozin, tofogliflozin, and ertugliflozin. Currently, no SGLT-2 inhibitors are FDA-approved for type 1 DM, although they have been used off-label and in trials in this patient population.

These drugs work by targeting the SGLT-2 protein in the kidney. In healthy individuals, 99% of filtered glucose is reabsorbed by the kidney with a filtered load of approximately 180 g/day.²³ Glucosuria occurs with glucose concentrations above this threshold. In patients with type 2 DM, this threshold and the ability to reabsorb glucose is increased, contributing to hyperglycemia.²⁴ Located in the proximal tubule, the SGLT-2 protein is responsible for 80% to 90% of glucose reabsorption, with SGLT-1 responsible for the other 10% to 20%.²⁵ Inhibition of SGLT-2 reduces the renal threshold for glucose, thus leading to glucosuria and reduction in serum glucose levels.²⁴ Table 4 lists dosing regimens, HbA1c effects, and side-effect profiles for the SGLT-2 inhibitors.

As a monotherapy, SGLT-2 inhibitors significantly reduce HbA1c levels by 0.4% to 1.1% when compared with placebo.^26–28 Reductions may be more significant in patients with HbA1c levels greater than 8.5%, and even more so in patients with HbA1c levels above 10%.²⁹ When compared with other therapeutic options for type 2 DM, SGLT-2 inhibitors have efficacy similar to metformin, sitagliptin, and glipizide; however, some studies have shown superiority to glimepiride and sitagliptin at reducing HbA1c, depending on the dose and duration of treatment.^26,27

The SGLT-2 inhibitors do not rely on insulin activity, allowing for their use at any stage of type 2 DM and in combination with other therapies, including insulin. As an add-on medication, SGLT-2 inhibitors reduce HbA1c by 0.5% to 0.7%.^27,28 Given that the mechanism of action depends on the filtered load of glucose, they are less effective in patients with a reduced glomerular filtration rate (GFR).

The SGLT-2 inhibitors have bene­fits beyond that of glycemic control. Studies report weight loss of 1 to 3 kg, which is maintained up to 104 weeks.^27–31 Sustained weight loss is secondary to glucosuria, which amounts to a caloric loss of 200 to 300 kcal/day.³⁰ Also, SGLT-2 inhibitors lead to modest reductions in systolic and diastolic blood pressure of approximately 3 to 6 mm Hg and 1 to 2 mm Hg, respectively, due to their diuretic effect.^27,31 The risk of hypoglycemia is low—similar to that of metformin and DPP-4 inhibitors—and only slightly higher than placebo when used as monotherapy.^26,31 When added to sulfonylureas or insulin, however, the risk of hypoglycemia is increased.^26,29

Meta-analyses of SGLT-2 inhibitors showed rates of death and other serious adverse effects were no different than placebo.^26,27 A 2015 study on the CV safety of empagliflozin showed lower rates of CV death (38% relative risk [RR] reduction), lower rates of hospitalization due to heart failure (35% RR reduction), and lower rates of all-cause mortality (32% RR reduction) when compared with placebo, with no difference in nonfatal stroke and MI.³² CV safety trials for dapagliflozin and canagliflozin are ongoing, although some trials have shown an increased incidence in CV events in the first 30 days of treatment with canagliflozin.⁴

Common side effects include genital infections, such as vaginitis and balanitis, as well as urinary tract infections. In a 2013 meta-analysis,²⁷ genital infections carried an odds ratio of 3.5 for SGLT-2 inhibitors compared with placebo, while urinary tract infections carried a 1.34 odds ratio. The increased risk of infection is thought to be secondary to glucosuria combined with immune dysfunction and altered glycosylation uroepithelium cells.³⁰

During clinical trials, more cases of bladder cancer were diagnosed in patients on dapagliflozin than on placebo, leading to a delay in FDA approval. No causal relationship was established, but dapagliflozin is not recommended in patients with active bladder cancer.³⁰

Treatment with SGLT-2 inhibitors can lead to a decrease in GFR, likely secondary to the diuretic effect. In patients with GFR greater than 60 mL/min, this decrease is transient. In patients with GFR below 60 mL/min (moderate renal impairment) who were treated with dapagliflozin, GFR did not quite return to baseline, and they did not show an improvement in HbA1c relative to placebo.³³ Canagliflozin at a dose of 300 mg/day caused renal-related adverse events with GFR 45 to 60 mL/min, but a lower dose of 100 mg/day did not.²⁷ A decrease in GFR also occurred in patients with chronic kidney disease treated with empagliflozin, which returned to baseline after discontinuing the drug.³¹ Despite these findings, renal function stabilizes in patients on SGLT-2 inhibitors over time, whereas it continues to decrease with placebo, suggesting there may be a renal protective effect.³⁰ Their diuretic effect can also lead to volume depletion in patients at risk such as elderly patients or those already taking diuretics.³¹

Some studies have shown mild increases in low-density lipoprotein (LDL) and high-density lipoprotein (HDL) levels with no change in triglycerides, though long-term effects of this are unknown.³¹

There are case reports of euglycemic diabetic ketoacidosis occurring in patients with type 1 DM and type 2 DM treated with SGLT-2 inhibitors, which led the FDA in May 2015 to issue a warning that SGLT-2 inhibitors may increase the risk of ketoacidosis.³⁴ There are several possible mechanisms for this increased risk. The SGLT-2 inhibitors may decrease renal clearance of ketones, stimulate glucagon secretion leading to hepatic ketogenesis, or suppress glucose-mediated insulin secretion leading practitioners to decrease insulin doses thus resulting in increased ketone production via lipolysis.³⁴ More studies are needed, but patients and healthcare providers should be aware of potential euglycemic ketoacidosis associated with SGLT-2-inhibitors, as the lack of hyperglycemia can delay the diagnosis.

BILE ACID SEQUESTRANTS

Bile acid sequestrants have been used for years in hyperlipidemia to reduce LDL concentration; however, colesevelam is the only drug in this class approved (2009) for treating type 2 DM, after studies showed colesevelam improves glycemic control.^35–37 Though several possibilities have been proposed, the precise mechanism of action for lowering blood glucose levels is unknown.³⁵ Colesevelam is not absorbed systemically and does not affect endogenous insulin levels.⁴ Table 4 lists dosing regimens, HbA1c effects, and side-effect profiles for colesevelam.

As monotherapy, studies have shown varying effectiveness in reducing HbA1c relative to placebo ranging from no statistical difference to 0.54% reduction.^36,37 As an add-on to other diabetic medications, a Cochrane review of six randomized controlled trials showed a decrease in HbA1c by 0.3% to 0.5% and decrease in fasting glucose of 15 mg/dL.³⁷ Additional benefits of colesevelam include low risk for hypoglycemia, weight neutrality, and reduction in LDL.⁴ No serious adverse events or deaths have been associated with colesevelam, including CV events; however, more trials on macrovascular outcomes are needed to clarify its side-effect profile.³⁵

Common side effects include constipation, flatulence, and dyspepsia.³⁵ Colesevelam has shown a statistically significant increase in triglycerides, so its use in patients with triglycerides above 500 mg/dL or with hypertriglyceridemia-induced pancreatitis is contraindicated.⁴ Caution should be used prior to starting treatment in patients with triglyceride levels above 200 mg/dL.³⁵ Colesevelam is contraindicated in patients with a history of small-bowel obstruction, and caution is recommended in patients with decreased gastric motility. This drug may reduce absorption of fat-soluble vitamins and some medications.⁴

Although further research into the long-term effects of colesevelam is needed, its relatively good safety profile makes it a reasonable choice in diabetic patients with hyperlipidemia not controlled with statins.

DOPAMINE-RECEPTOR AGONIST

Bromocriptine, a dopamine-receptor agonist, was FDA-approved for the treatment of Parkinson disease, hyperprolactinemia, and acromegaly in the 1970s. In 2009, a quick-release formulation of bromocriptine (bromocriptine QR) was approved for treatment of type 2 DM. Table 4 lists dosing regimens, HbA1c effects, and side-effect profiles for bromocriptine.

The precise mechanism of action is unclear, but an American Association of Clinical Endocrinologists expert panel recommendation suggests that it may lower glucose levels by improving hypothalamic-mediated, postprandial insulin sensitivity via increasing morning dopaminergic activity (decreased in patients with type 2 DM) and by reducing hypothalamic adrenergic tone.³⁸ It is not currently recommended as monotherapy, although a study of 154 patients showed monotherapy reduced HbA1c by 0.55%.³⁹ When added to other diabetic medications, it reduced HbA1c by 0.4% to 0.7%.^4,38

Bromocriptine QR is weight neutral and carries a low risk of hypoglycemia.⁴ A safety trial with 3,095 patients showed fewer adverse CV events in patients treated with bromocriptine QR compared with placebo, which may be secondary to reduced sympathetic tone or to reduced systemic inflammation.⁴⁰ Some studies have shown reductions in blood pressure, free fatty acid levels, and triglycerides, with no change in LDL or HDL.³⁸

Common side effects include nausea, headache, dizziness, diarrhea, and fatigue. Administration is recommended with food to reduce GI side effects. It is contraindicated in women who are nursing and those with syncopal migraines. Furthermore, it may be prudent to avoid this medication in patients with a history of psychosis, those currently treated with dopamine agonists or antagonists, or those at risk for hypotension.⁴

CONCLUSION

The pathophysiology of type 2 DM involves at least seven organs and tissues—the brain, liver, pancreas, intestines, kidneys, fat, and muscle—and no single medication addresses all seven of them. Most patients require more than one medication to adequately treat their diabetes, making availability and development of drugs with unique and complementary mechanisms of action of paramount importance. The medications described here—DPP-4 inhibitors, GLP-1 agonists, SGLT-2 inhibitors, colesevelam, and bromocriptine QR—provide therapeutic options with novel mechanisms of action, all while avoiding weight gain and providing a low risk of hypoglycemia. While not appropriate for every patient, these medications give healthcare providers additional options to individualize treatment and optimize care for patients.
 

Acknowledgments. The authors gratefully thank Julie Benke-Bennett for assistance with manuscript formatting and transcription. The contents of this article do not represent the views of the Department of Veterans Affairs or the United States Government.

Type 2 diabetes mellitus (DM) is caused by hyperglycemia and metabolic alterations due to abnormalities in insulin secretion or insulin action, or both. To achieve desired glycemic targets, different antihyperglycemic drugs are used alone or in combination with other agents, including insulin. First-line options for diabetes treatment are weight loss, lifestyle modification, and metformin. The American Diabetes Association and the European Association for the Study of Diabetes recommend a patient-specific treatment approach to enhance glycemic control while avoiding weight gain and hypoglycemia.¹ This review will focus on the newer oral agents and injectable noninsulin agents that are used to achieve glycemic control. Table 1 lists the noninsulin drugs approved since 2005.

INCRETIN-BASED THERAPIES

The incretins are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which are secreted by the gastrointestinal (GI) tract in response to food intake. Both GLP-1 and GIP stimulate beta cells of the pancreas, which contribute 60% of the insulin secretion after a meal. Type 2 DM is associated with decreased secretion of GLP-1 and lowered responsiveness to GIP. Benefits of the incretin hormones on glycemic control include enhanced satiety, decreased GI motility, increased glucose-dependent insulin secretion, reduced glucagon secretion, and decreased hepatic glucose release.² Two incretin-based drug classes are used to treat patients with type 2 DM—oral dipeptidyl peptidase-4 (DPP-4) inhibitors and GLP-1 receptor agonists.

DPP-4 inhibitors

The oral DPP-4 inhibitors block the degradation of the enzyme DPP-4 active site and thus increase the GLP-1 and GIP concentrations by two to three times. Their primary effectiveness centers on controlling insulin and glucagon secretion without increasing weight.

Four DPP-4 inhibitors are approved by the US Food and Drug Administration (FDA) in once-daily oral formulations: sitagliptin, saxagliptin, linagliptin, and alogliptin. Another DPP-4 inhibitor, vildagliptin, is not licensed in the United States but is approved for use in Europe and Japan.³ Another DPP-4 inhibitor, teneligliptin, is also marketed in Japan.

The DPP-4 inhibitors are indicated for use as monotherapy or in combination with other agents such as metformin, sulfonylureas, thiazolidinediones, and insulin. Generally, DPP-4 inhibitors do not cause hypoglycemia when used as monotherapy.¹ When adding a DPP-4 inhibitor to a sulfonylurea or insulin, it is recommended to decrease the sulfonylurea or insulin dose to reduce the risk of hypoglycemia. The potential of these agents to lower the hemoglobin A1c (HbA1c) when used as monotherapy and in combination with metformin, sulfonylureas, or thiazolidine­diones is 0.3% to 0.71%.⁴

The DPP-4 inhibitors are not known to cause adverse GI effects. Sitagliptin, alogliptin, vildagliptin, and saxagliptin need dosing adjustments for renal insufficiency; however, linagliptin is not renally eliminated and does not require dosing adjustment. Common adverse events (> 5%) are nasopharyngitis, upper-respiratory infection, and headache. Sitagliptin and saxagliptin have been associated with urinary tract infection. Sitagliptin also has been associated with more extremity pain, back pain, and osteoarthritis.⁴

The DPP-4 inhibitors are primarily excreted by the renal or fecal route and, therefore, have few drug interactions. All DPP-4 inhibitors are partially metabolized through cytochrome P450 enzymes, except saxagliptin.⁴ Their pharmacokinetic profiles are shown on Table 2.

In keeping with the FDA guidelines, sitagliptin, saxagliptin, linagliptin, and alogliptin have been evaluated for cardiovascular (CV) outcomes. The SAVOR-TIMI 53 clinical trial (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients With Diabetes Mellitus–Thrombolysis in Myocardial Infarction 53) was a 2-year CV safety and efficacy trial.⁵ This trial demonstrated no statistically significant difference in the primary end point as a composite of CV death, myocardial infarction (MI), and ischemic stroke. Additionally, the secondary end points, including hospitalization for unstable angina, coronary revascularization, and heart failure, also did not show significant difference. However, based on a subgroup analysis, there was a statistically significant increase in patients in the saxagliptin group vs the placebo group who were hospitalized for heart failure.

A 2-year trial comparing linagliptin with glimepiride, a second-generation sulfonylurea, showed significantly fewer CV events with linagliptin.⁶ This trial found a relative risk reduction of 54% in the end points of CV death, nonfatal MI or stroke, and unstable angina during hospitalization.^4,6 Another trial reviewed the incidence of CV events (CV death, nonfatal MI, and nonfatal stroke) in patients treated with alogliptin, placebo, or comparator antihyperglycemic drugs and found no increased incidence of major adverse CV events vs comparator therapies.⁷

The recently published TECOS (Trial Evaluating Cardiovascular Outcomes With Sitagliptin), reported no increase in major atherosclerotic CV events, no difference in all-cause mortality, and no difference in heart failure for hospitalization or other adverse events in patients with type 2 DM.⁸ Other clinical trials such as the CAROLINA study (linagliptin compared with glimepiride),⁹ the EXAMINE study (alogliptin),¹⁰ and the CARMALINA study (linagliptin)¹¹ are also reviewing the CV safety of DPP-4 inhibitors in the United States.

Concern has been raised about the association between incretin-based therapies and adverse pancreatic effects. CV outcomes trials using saxagliptin and alogliptin found similar rates of pancreatitis and fewer pancreatic cancer cases in comparison with placebo.^5,7,10 TECOS demonstrated that with sitagliptin, acute pancreatitis occurred more in the sitagliptin group, but there was no statistical significance reported. However, pancreatic cancer occurred more in the placebo group, although the difference was not statistically significant.⁸ Neither the FDA nor the European Medicines Agency (EMA) has reached a firm conclusion about the possible association between incretin-based therapies and pancreatitis or pancreatic cancer.¹²

GLP-1 agonists

The GLP-1 drugs mimic the action of native GLP-1. Several GLP-1 agents are available in the United States, and several more are in development.^11,13 The drug class is divided into three groups:

• Short-acting (4–6 hours): exenatide, lixisenatide
• Intermediate-acting (24 hours): liraglutide
• Long-acting (7 days): exenatide extended-release (ER), dulaglutide, and albiglutide (semaglutide is in phase 3 study).

The GLP-1 receptor agonists heighten glucose homeostasis by the following mechanisms of action: stimulate insulin secretion, suppress glucagon secretion, directly and indirectly inhibit endogenous glucose production, promote satiety, heighten insulin sensitivity due to weight loss, and slow gastric emptying time. Table 3 lists dosing and pharmacokinetic profiles for GLP-1 agonists. When GLP-1 agonists are used as monotherapy, the HbA1c is reduced by 0.7% to 1.51%.¹³ When GLP-1 agonists are used in combination with metformin, sulfonylureas, thiazolidinediones, or as three-drug therapy with other oral antidiabetic medications, the HbA1c is lowered by 0.4% to 1.9%.^13–17

A notable advantage of GLP-1 agonists is their effect on weight loss separate from GI side effects. Weight reductions of 0.2 to 3.6 kg in 26 weeks have been seen with the exenatide formulations, liraglutide, albiglutide, and dulaglutide.^13,18 Liraglutide has demonstrated a greater weight reduction than exenatide, exenatide ER, or albiglutide.^13,16,17 There were similar weight reductions of 1.5 kg in 26 weeks in a comparator trial involving liraglutide and dulaglutide (3.6 vs 2.9 kg).¹⁹

Common adverse effects of the GLP-1 agonists are nausea (8% to 44%), diarrhea (6% to 20%), and vomiting (4% to 18%), which may occur initially and diminish with continued use.^13,14 There have been more GI side effects with liraglutide than with exenatide ER or albiglutide.²⁰ Increased rates of injection site reactions, such as transient small nodule formations, were seen with exenatide ER (5.4% to 17.6%) and albiglutide, the once-weekly GLP-1 agonist therapies, vs exenatide, liraglutide, and insulin glargine.^13,14 Dulaglutide, another once-weekly GLP-1 agonist, does not have this finding; however, there is enhanced patient satisfaction with the once-weekly preparations in comparison with the twice-daily preparations.^14,16 Patients who received albiglutide have noted hypersensitivity reactions such as pruritus, rash, and dyspnea (10% to 18%).¹³ Hypoglycemia is not seen with the GLP-1 agonists, unless they are used in conjunction with a sulfonylurea or insulin.

Exenatide and exenatide ER are excreted by the renal route; therefore, it is not recommended to use these agonists in patients with renal impairment or end-stage renal disease (creatinine clearance [CrCl] < 30 mL/min). Liraglutide is not excreted by the renal route; however, it should be used with caution in patients with renal impairment.²¹ No renal dose adjustment is required when using albiglutide or dulaglutide.²¹

Clinical trials have demonstrated the short-term CV outcomes of GLP-1 agonists. The CV benefits include a decrease in blood pressure, reduction of lipid levels, enhanced endothelial function, and improved myocardial function.¹³ One meta-analysis reported a tendency for lowering the rate of major CV events, stroke, MI, CV mortality, and all-cause mortality.²² Several ongoing trials are evaluating the safety of GLP-1 agonists and CV safety: LEADER (liraglutide), EXSCEL (exenatide LR), ELIXA (lixisenatide), SUSTAIN 6 (semaglutide), and REWIND (dulaglutide).¹¹

The GLP-1 agonists have been linked to an increased incidence of thyroid cancer. There was a potential increased risk of thyroid cancer in preclinical rodent studies involving liraglutide and exenatide ER, but this risk was not demonstrated for the exenatide twice-daily preparation.¹³ The FDA noted that the findings from rodent studies, which demonstrated a possible heightened risk for thyroid cancer, should not be conveyed to the outcomes for humans. Nevertheless, when liraglutide was approved in January 2010, the FDA issued a boxed warning about the risk of thyroid C-cell hyperplasia. The package inserts list a thyroid carcinoma risk for exenatide ER, liraglutide, albiglutide, and dulaglutide in those patients with a personal or family history of medullary thyroid cancer.

There is controversy about the incidence of pancreatitis and pancreatic cancer with the use of the incretin-based therapies. Published studies and case reports seem to support speculation that there is an increased incidence of acute pancreatitis associated with type 2 DM.²¹ The FDA and the EMA have independently reviewed postmarketing reports about pancreatitis and pancreatic cancer among more than 28,000 patients who received some form of incretin-based therapy.¹² They independently agreed that a causal association between incretin-based drugs and pancreatitis or pancreatic cancer is inconsistent with the current data.¹² At this time, there is no final conclusion about a causal relationship between the use of incretin-based drugs and possible pancreatitis and pancreatic cancer.

SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS

In 2013, canagliflozin became the first sodium-glucose cotransporter-2 (SGLT-2) inhibitor to be FDA-approved for treating patients with type 2 DM, followed in 2014 by dapagliflozin and empagliflozin. Several other drugs in this class are available outside the US or are currently undergoing clinical development, including ipragliflozin, luseogliflozin, tofogliflozin, and ertugliflozin. Currently, no SGLT-2 inhibitors are FDA-approved for type 1 DM, although they have been used off-label and in trials in this patient population.

These drugs work by targeting the SGLT-2 protein in the kidney. In healthy individuals, 99% of filtered glucose is reabsorbed by the kidney with a filtered load of approximately 180 g/day.²³ Glucosuria occurs with glucose concentrations above this threshold. In patients with type 2 DM, this threshold and the ability to reabsorb glucose is increased, contributing to hyperglycemia.²⁴ Located in the proximal tubule, the SGLT-2 protein is responsible for 80% to 90% of glucose reabsorption, with SGLT-1 responsible for the other 10% to 20%.²⁵ Inhibition of SGLT-2 reduces the renal threshold for glucose, thus leading to glucosuria and reduction in serum glucose levels.²⁴ Table 4 lists dosing regimens, HbA1c effects, and side-effect profiles for the SGLT-2 inhibitors.

As a monotherapy, SGLT-2 inhibitors significantly reduce HbA1c levels by 0.4% to 1.1% when compared with placebo.^26–28 Reductions may be more significant in patients with HbA1c levels greater than 8.5%, and even more so in patients with HbA1c levels above 10%.²⁹ When compared with other therapeutic options for type 2 DM, SGLT-2 inhibitors have efficacy similar to metformin, sitagliptin, and glipizide; however, some studies have shown superiority to glimepiride and sitagliptin at reducing HbA1c, depending on the dose and duration of treatment.^26,27

The SGLT-2 inhibitors do not rely on insulin activity, allowing for their use at any stage of type 2 DM and in combination with other therapies, including insulin. As an add-on medication, SGLT-2 inhibitors reduce HbA1c by 0.5% to 0.7%.^27,28 Given that the mechanism of action depends on the filtered load of glucose, they are less effective in patients with a reduced glomerular filtration rate (GFR).

The SGLT-2 inhibitors have bene­fits beyond that of glycemic control. Studies report weight loss of 1 to 3 kg, which is maintained up to 104 weeks.^27–31 Sustained weight loss is secondary to glucosuria, which amounts to a caloric loss of 200 to 300 kcal/day.³⁰ Also, SGLT-2 inhibitors lead to modest reductions in systolic and diastolic blood pressure of approximately 3 to 6 mm Hg and 1 to 2 mm Hg, respectively, due to their diuretic effect.^27,31 The risk of hypoglycemia is low—similar to that of metformin and DPP-4 inhibitors—and only slightly higher than placebo when used as monotherapy.^26,31 When added to sulfonylureas or insulin, however, the risk of hypoglycemia is increased.^26,29

Meta-analyses of SGLT-2 inhibitors showed rates of death and other serious adverse effects were no different than placebo.^26,27 A 2015 study on the CV safety of empagliflozin showed lower rates of CV death (38% relative risk [RR] reduction), lower rates of hospitalization due to heart failure (35% RR reduction), and lower rates of all-cause mortality (32% RR reduction) when compared with placebo, with no difference in nonfatal stroke and MI.³² CV safety trials for dapagliflozin and canagliflozin are ongoing, although some trials have shown an increased incidence in CV events in the first 30 days of treatment with canagliflozin.⁴

Common side effects include genital infections, such as vaginitis and balanitis, as well as urinary tract infections. In a 2013 meta-analysis,²⁷ genital infections carried an odds ratio of 3.5 for SGLT-2 inhibitors compared with placebo, while urinary tract infections carried a 1.34 odds ratio. The increased risk of infection is thought to be secondary to glucosuria combined with immune dysfunction and altered glycosylation uroepithelium cells.³⁰

During clinical trials, more cases of bladder cancer were diagnosed in patients on dapagliflozin than on placebo, leading to a delay in FDA approval. No causal relationship was established, but dapagliflozin is not recommended in patients with active bladder cancer.³⁰

Treatment with SGLT-2 inhibitors can lead to a decrease in GFR, likely secondary to the diuretic effect. In patients with GFR greater than 60 mL/min, this decrease is transient. In patients with GFR below 60 mL/min (moderate renal impairment) who were treated with dapagliflozin, GFR did not quite return to baseline, and they did not show an improvement in HbA1c relative to placebo.³³ Canagliflozin at a dose of 300 mg/day caused renal-related adverse events with GFR 45 to 60 mL/min, but a lower dose of 100 mg/day did not.²⁷ A decrease in GFR also occurred in patients with chronic kidney disease treated with empagliflozin, which returned to baseline after discontinuing the drug.³¹ Despite these findings, renal function stabilizes in patients on SGLT-2 inhibitors over time, whereas it continues to decrease with placebo, suggesting there may be a renal protective effect.³⁰ Their diuretic effect can also lead to volume depletion in patients at risk such as elderly patients or those already taking diuretics.³¹

Some studies have shown mild increases in low-density lipoprotein (LDL) and high-density lipoprotein (HDL) levels with no change in triglycerides, though long-term effects of this are unknown.³¹

There are case reports of euglycemic diabetic ketoacidosis occurring in patients with type 1 DM and type 2 DM treated with SGLT-2 inhibitors, which led the FDA in May 2015 to issue a warning that SGLT-2 inhibitors may increase the risk of ketoacidosis.³⁴ There are several possible mechanisms for this increased risk. The SGLT-2 inhibitors may decrease renal clearance of ketones, stimulate glucagon secretion leading to hepatic ketogenesis, or suppress glucose-mediated insulin secretion leading practitioners to decrease insulin doses thus resulting in increased ketone production via lipolysis.³⁴ More studies are needed, but patients and healthcare providers should be aware of potential euglycemic ketoacidosis associated with SGLT-2-inhibitors, as the lack of hyperglycemia can delay the diagnosis.

BILE ACID SEQUESTRANTS

Bile acid sequestrants have been used for years in hyperlipidemia to reduce LDL concentration; however, colesevelam is the only drug in this class approved (2009) for treating type 2 DM, after studies showed colesevelam improves glycemic control.^35–37 Though several possibilities have been proposed, the precise mechanism of action for lowering blood glucose levels is unknown.³⁵ Colesevelam is not absorbed systemically and does not affect endogenous insulin levels.⁴ Table 4 lists dosing regimens, HbA1c effects, and side-effect profiles for colesevelam.

As monotherapy, studies have shown varying effectiveness in reducing HbA1c relative to placebo ranging from no statistical difference to 0.54% reduction.^36,37 As an add-on to other diabetic medications, a Cochrane review of six randomized controlled trials showed a decrease in HbA1c by 0.3% to 0.5% and decrease in fasting glucose of 15 mg/dL.³⁷ Additional benefits of colesevelam include low risk for hypoglycemia, weight neutrality, and reduction in LDL.⁴ No serious adverse events or deaths have been associated with colesevelam, including CV events; however, more trials on macrovascular outcomes are needed to clarify its side-effect profile.³⁵

Common side effects include constipation, flatulence, and dyspepsia.³⁵ Colesevelam has shown a statistically significant increase in triglycerides, so its use in patients with triglycerides above 500 mg/dL or with hypertriglyceridemia-induced pancreatitis is contraindicated.⁴ Caution should be used prior to starting treatment in patients with triglyceride levels above 200 mg/dL.³⁵ Colesevelam is contraindicated in patients with a history of small-bowel obstruction, and caution is recommended in patients with decreased gastric motility. This drug may reduce absorption of fat-soluble vitamins and some medications.⁴

Although further research into the long-term effects of colesevelam is needed, its relatively good safety profile makes it a reasonable choice in diabetic patients with hyperlipidemia not controlled with statins.

DOPAMINE-RECEPTOR AGONIST

Bromocriptine, a dopamine-receptor agonist, was FDA-approved for the treatment of Parkinson disease, hyperprolactinemia, and acromegaly in the 1970s. In 2009, a quick-release formulation of bromocriptine (bromocriptine QR) was approved for treatment of type 2 DM. Table 4 lists dosing regimens, HbA1c effects, and side-effect profiles for bromocriptine.

The precise mechanism of action is unclear, but an American Association of Clinical Endocrinologists expert panel recommendation suggests that it may lower glucose levels by improving hypothalamic-mediated, postprandial insulin sensitivity via increasing morning dopaminergic activity (decreased in patients with type 2 DM) and by reducing hypothalamic adrenergic tone.³⁸ It is not currently recommended as monotherapy, although a study of 154 patients showed monotherapy reduced HbA1c by 0.55%.³⁹ When added to other diabetic medications, it reduced HbA1c by 0.4% to 0.7%.^4,38

Bromocriptine QR is weight neutral and carries a low risk of hypoglycemia.⁴ A safety trial with 3,095 patients showed fewer adverse CV events in patients treated with bromocriptine QR compared with placebo, which may be secondary to reduced sympathetic tone or to reduced systemic inflammation.⁴⁰ Some studies have shown reductions in blood pressure, free fatty acid levels, and triglycerides, with no change in LDL or HDL.³⁸

Common side effects include nausea, headache, dizziness, diarrhea, and fatigue. Administration is recommended with food to reduce GI side effects. It is contraindicated in women who are nursing and those with syncopal migraines. Furthermore, it may be prudent to avoid this medication in patients with a history of psychosis, those currently treated with dopamine agonists or antagonists, or those at risk for hypotension.⁴

CONCLUSION

The pathophysiology of type 2 DM involves at least seven organs and tissues—the brain, liver, pancreas, intestines, kidneys, fat, and muscle—and no single medication addresses all seven of them. Most patients require more than one medication to adequately treat their diabetes, making availability and development of drugs with unique and complementary mechanisms of action of paramount importance. The medications described here—DPP-4 inhibitors, GLP-1 agonists, SGLT-2 inhibitors, colesevelam, and bromocriptine QR—provide therapeutic options with novel mechanisms of action, all while avoiding weight gain and providing a low risk of hypoglycemia. While not appropriate for every patient, these medications give healthcare providers additional options to individualize treatment and optimize care for patients.
 

Acknowledgments. The authors gratefully thank Julie Benke-Bennett for assistance with manuscript formatting and transcription. The contents of this article do not represent the views of the Department of Veterans Affairs or the United States Government.

The first isolation and successful extraction of insulin in 1921 opened an important chapter in the management of diabetes, especially for patients with profound insulin deficiency. At that time, a 14-year-old patient who was dying from type 1 diabetes received the first insulin injection—a canine pancreatic extract. It was a lifesaving treatment. Within a few months of insulin administration, the patient regained weight and health and went on to live another 13 years before succumbing to pneumonia and chronic complications of hyperglycemia.

While the introduction of regular insulin from animal extracts provided lifesaving therapy for patients with type 1 diabetes, it was the introduction of protaminated insulin in 1946 that provided more extended “basal” coverage to taper some of the large glycemic fluctuations that occurred with the administration of regular insulin two to three times daily. The use of a split-mix approach with twice-daily administration of a combination of regular insulin plus either insulin neutral protamine Hagedorn (NPH) or insulin lente provided overall better control with fewer episodes of hypoglycemia or severe hyperglycemia.

Insulin was the first protein to be sequenced (in 1955), and it became the first human protein to be manufactured through human recombinant technology. It was introduced into clinical practice in 1982 as synthetic “human” insulin, with the advantage of being less allergenic than animal insulin preparations. Human insulin eventually replaced all of the animal insulin preparations in the US market.

The pursuit of tight glycemic control as an effective strategy to prevent the chronic and devastating complications of the disease was confirmed in 1993 by publication of the Diabetes Control and Complications Trial (DCCT), which undeniably established the relationship between normalization of glycemia and prevention of microvascular complications in patients with type 1 diabetes.¹ The UK Prospective Diabetes Study, demonstrating a similar relationship in type 2 diabetes, was soon to follow.² In both trials, the follow-up observation periods further underscored the importance of early glycemic control by showing both sustained reductions in microvascular complications (retinopathy, nephropathy, and neuropathy) and statistically significant decreases in the risk of a cardiovascular event.^3,4 Of note, it was the introduction in clinical practice of safer and more user-friendly insulin options that made these gains in glycemic control possible.

With the publication of the DCCT results,¹ physio­logic insulin replacement became the therapeutic standard in patients with advanced insulin deficiency, demonstrating that lowering hemoglobin A1c (HbA1c) and mitigating glycemic variability translated into microvascular risk reduction. The use of longer-acting insulin preparations, such as ultralente insulin, and the delivery of the basal component through continuous subcutaneous (SC) insulin infusion using an insulin pump further facilitated achievement of near-normal glycemia.

Insulin products continue to be refined and new formulations and molecular entities developed (Table 1). The following sections review the current insulin products, their pharmacologic profiles, and their clinical roles in diabetes practice.

INSULIN ANALOGUES

In 1996, the first short-acting insulin analogue (or insulin-receptor ligand), lispro, was brought to market. In lispro, the penultimate lysine and proline amino acids on the end of the C-terminal of the beta-chain of human insulin are reversed, facilitating faster absorption of the insulin through the greater availability of insulin monomers following SC depot injection.

The three short-acting insulin analogues—lispro, aspart, and glulisine—have similar pharmacokinetic and pharmacodynamic properties, with earlier onset and peak of biologic action, and shorter duration of activity than regular insulin. Potentially, these characteristics should translate into greater administration flexibility (patients can inject anywhere from 20 minutes before to 20 minutes after the start of the meal), better control of postprandial hyperglycemia, and less risk of late prandial hypoglycemia (3 to 6 hours after the meal). In a meta-analysis comparing short-acting analogues with human regular insulin, the most relevant difference reported was a lower risk of severe hypoglycemia with the analogue preparations⁵ (Table 2). There might be an advantage with regards to bedtime and overnight hypoglycemia when using short-acting analogues, especially if a protaminated insulin is used for overnight basal coverage.⁶

While short-acting analogues have been approved for administration following a meal, postprandial control is clearly better if these preparations are injected prior to the meal, ideally 15 to 20 minutes before, to allow time to enter the circulation.⁷ Additionally, the pharmacokinetics and biologic activity of short-acting insulin analogues appear to be very different when administered to obese, insulin-resistant patients with type 2 diabetes, in whom the onset of action is delayed and the biologic activity considerably reduced.⁸

INHALED INSULIN

Data from Afrezza (insulin human) inhalation powder [package insert]. Danbury, CT: MannKind Corp; 2014.

A recent entry into the short-acting insulin marketplace—Technosphere oral-inhaled insulin (Afrezza)—was US Food and Drug Administration (FDA)-approved in 2014. Inhaled insulin has low bioavailability but is absorbed much more rapidly into the circulation than the current short-acting insulin analogues and has a shorter duration of biologic activity. However, the pharmacodynamics of inhaled insulin, when compared with insulin lispro, show only a slightly faster onset of action and a lower peak of biologic activity⁹ (Figure 1). Studies comparing the efficacy and safety of inhaled insulin with short-acting analogues or premix insulin have demonstrated equivalent or less effective blood glucose-lowering effect and equivalent or lower risk of hypoglycemia.¹⁰ For example, in trials of aspart insulin in patients with type 1 diabetes, inhaled insulin had statistically less reduction in HbA1c; in only one of the two trials did it show less hypoglycemia risk. Another trial comparing inhaled insulin plus basal insulin to premix aspart 70/30 showed equivalent HbA1c reductions, but less hypoglycemia with inhaled insulin.¹⁰

Inhaled insulin should not be used by smokers, patients with chronic lung disease (such as asthma and chronic obstructive pulmonary disease), and those with acute episodes of bronchospasm. In patients who have a history of or are at risk for lung cancer, the benefits of using inhaled insulin need to be carefully weighed against the potential risks, especially given the increase in lung cancer events in smokers that was observed with the prior inhaled-insulin preparation Exubera.¹¹ Baseline and follow-up spirometry needs to be implemented for those using inhaled insulin to exclude clinically significant changes in forced expiratory volume in 1 second. Dosing of inhaled technosphere insulin is done via single-use cartridges of 4-, 8-, or 12-unit composition, making titration of smaller insulin increments more of a challenge. Patient reported outcomes in trials of inhaled insulin report variable effect (equivalent or favorable) on diabetes worries, health-related quality of life, or perceptions of insulin therapy, satisfaction, or preference.^12,13

CONCENTRATED INSULIN

Concentrated insulin preparations have been available in clinical practice for many years and have been implemented with variable success. For example, Humulin R U-500 is a concentrated human regular insulin product (five times more concentrated than U-100) that has been used in patients requiring consistently high daily doses of insulin (usually > 200 U/day). Nonrandomized studies have shown significant improvement in glycemic control comparing pre- and post-intervention periods in patients switched from U-100 prandial insulin preparations to U-500 regular insulin.¹⁴ Given the slight differences in pharmacodynamic profiles between regular U-100 and U-500 insulin preparations,¹⁵ a randomized controlled trial comparing a U-500 insulin strategy with other currently available alternatives in very insulin-resistant patients will be needed to draw objective conclusions regarding the efficacy and safety of this concentrated insulin preparation.

For patients and providers who opt for a trial of regular U-500 insulin, a number of issues need to be considered to mitigate risks and optimize benefits of using this concentrated insulin. First and foremost is the frequent confusion in the communication between provider, pharmacy, and patient regarding the correct insulin dose to be administered. Because regular U-500 insulin is administered with U-100 insulin syringes, a 1-unit measure of U-500 corresponds to a 5-unit delivery of regular insulin.

To minimize confusion, regular U-500 prescriptions should be made out in volume rather than units, but this difference must be clearly explained to patients to avoid overdosing. For example, 0.01 mL of U-500 equates to 5 units of insulin, but it corresponds to the 1-unit mark of the standard U-100 insulin syringe. Newer concentrated insulin preparations on the market have avoided this confusion by providing measured doses in an insulin pen delivery system. For example, insulin lispro U-200 (Humalog U-200), a twofold concentration of insulin lispro U-100 with similar pharmacodynamics, is only available in a prefilled pen. Using insulin pen technology, a 1-unit dose of insulin actually corresponds to 1 unit of insulin, thereby removing any possible confusion regarding the prescription or administration of the correct insulin dose. Insulin lispro U-200 offers the convenience of holding more insulin per pen; it contains 600 units of insulin per pen compared with 300 units in the lispro U-100 pen.

BASAL INSULIN

Currently available basal insulin preparations include insulin NPH (Humulin N, Novolin N), insulin glargine U-100 (Lantus), insulin detemir (Levemir), and the 2015 FDA-approved formulations insulin glargine U-300 (Toujeo) and insulin degludec (Tresiba). The basal analogues introduced in the year 2000 with glargine U-100 were meant to fill the void left when the long-acting insulin ultralente animal preparations were pulled from the market in the early 1990s. The basal analogues have a longer duration of action than insulin NPH and, more importantly, have more stable and consistent biologic activity over a 24-hour period, resulting in more predictable glycemic levels and a lower risk of hypoglycemia.^16–18

Three insulin analogue preparations—glargine U-300 and degludec (both FDA-approved) and pegylated lispro (currently in phase 3 trials)—have demonstrated longer protraction of biologic activity than glargine U-100, considered the current technical standard for basal insulin replacement. These three “second-generation” basal insulin analogues have pharmacodynamic activity that extends beyond 24 hours. When compared with glargine U-100 insulin, they exhibited fewer pronounced peaks of biologic activity and less pharmacokinetic variability, with similar glycemic control (as determined by HbA1c) but with an even lower risk of hypoglycemia, especially nocturnal hypoglycemia.^19–21

The extended biologic activity raises concern for potential insulin stacking and subsequent hypoglycemia, which should be easily mitigated by restricting basal insulin dose adjustments to no more frequently than every 3 to 4 days, which corresponds to the time needed for these preparations to reach 90% or more of their effective steady state²² (Figure 2). Indeed, most of the clinical trials comparing these basal insulin preparations with glargine U-100 show a lower risk of hypoglycemia when basal dose adjustments are carried out weekly and no more frequently than every 3 days.²³

Insulin glargine U-300 is essentially a threefold concentrated preparation of insulin glargine U-100 that results in a two-thirds volume reduction and a one-half reduction in depot surface following SC administration. The reduced depot surface area is presumed to account for much of the protracted absorption of glargine U-300 from the SC tissues. The metabolism and elimination of glargine U-300 is similar to that of the original compound, with formation of two active metabolites: M1 (the principal active moiety) and M2. Biologic steady state is achieved after 4 to 5 days of once-daily injections.²⁴

When compared with glargine U-100 in patients with type 1 diabetes, insulin glargine U-300 at doses of 0.4 U/kg produced more stable insulin concentrations and glucose-lowering effect with a longer duration of action at steady state, as reflected by tight glucose control being maintained for about 5 hours longer (median of 30 hours).²⁵ A meta-analysis of the EDITION I to III clinical trials in patients with type 2 diabetes at various stages of treatment found similar glucose-lowering effects for glargine U-300 compared with glargine U-100 but a lower rate of nonsevere hypoglycemia.²⁰ Of note was the need for 10% to 15% more units of insulin for glargine U-300 in these clinical trials. Insulin glargine U-300 is available only in a 1.5 mL disposable prefilled pen, which contains 450 units of insulin. Because the dose counter on the pen window corresponds to the actual number of units of insulin to be injected, no dose recalculation is required by the patient or provider.

Insulin degludec is another ultra-long-acting basal insulin analogue with a half-life at steady state of greater than 25 hours.²⁶ In comparison, the half-life of insulin glargine U-100 in that same study was reported as 12.1 hours. Further, insulin degludec exhibited flatter and more stable biologic activity, more evenly distributed over the course of a 24-hour period than insulin glargine U-100. The protraction mechanism is based on the formation of long strings of multihexamers, facilitated by a 16-carbon fatty acid chain linked via a glutamic acid spacer to the terminal end of the B-chain of the insulin molecule.²⁷ In studies of patients with type 2 diabetes at various stages of treatment, insulin degludec also demonstrated lower risk of nonsevere hypoglycemia for an equivalent level of HbA1c control achieved.¹⁹

The flexibility of administration time for an ultra-long-acting insulin preparation such as degludec was tested by asking patients to alternate the injection of degludec between morning and evening, in effect creating administration intervals of up to 8 to 40 hours.²⁸ Even within such drastic parameters, the efficacy and safety of insulin degludec were maintained when compared with insulin glargine U-100 injected at the same time of the day every day.

Because of an increase in major adverse cardiovascular events in phase 3 trials, degludec is undergoing a cardiovascular safety trial in patients with type 2 diabetes. The DEVOTE trial, which started in October 2013, will include 7,500 patients and will continue for up to 5 years. Interim results have recently been submitted to the FDA resulting in conditional approval of degludec in the US (Clinical Trials.gov Registration: NCT01959529). Degludec is available in disposable pen or cartridge format in U-100 and U-200 formulations.

COST

These new insulin preparations have introduced clinical options that have efficacy similar to that of available insulin products but, for the most part, have advantages of safety (less risk of nonsevere hypoglycemia) and patient convenience (flexibility in timing of insulin dose administration). While the latter is presumed to improve patient adherence, this has yet to be confirmed. Compared with synthetic human insulin preparations (regular insulin, NPH, and premix 70/30 insulin), which can be obtained in certain pharmacies at a discount (usually around 3 cents per unit of insulin), the currently available insulin analogues are considerably more expensive (around 16 to 27 cents per unit of insulin).

Within the guidelines for initiation and intensification of the insulin regimen using basal insulin formulations, the clinician will need to balance the potential benefits and current costs for the treatment of the individual patient. Clearly, as patients with diabetes are brought closer to their glycemic goals with insulin options, they stand to increasingly bene­fit from formulations that provide more consistent glycemic response and less risk of hypoglycemia. For those who are unable to afford the higher costs, especially if their glycemic control is far from the desired target, the use of synthetic human insulin formulations may be entirely appropriate. In this era of individualized care and prescriptions, clinicians have a range of insulin treatment options that will facilitate patients reaching appropriate goals.

The first isolation and successful extraction of insulin in 1921 opened an important chapter in the management of diabetes, especially for patients with profound insulin deficiency. At that time, a 14-year-old patient who was dying from type 1 diabetes received the first insulin injection—a canine pancreatic extract. It was a lifesaving treatment. Within a few months of insulin administration, the patient regained weight and health and went on to live another 13 years before succumbing to pneumonia and chronic complications of hyperglycemia.

While the introduction of regular insulin from animal extracts provided lifesaving therapy for patients with type 1 diabetes, it was the introduction of protaminated insulin in 1946 that provided more extended “basal” coverage to taper some of the large glycemic fluctuations that occurred with the administration of regular insulin two to three times daily. The use of a split-mix approach with twice-daily administration of a combination of regular insulin plus either insulin neutral protamine Hagedorn (NPH) or insulin lente provided overall better control with fewer episodes of hypoglycemia or severe hyperglycemia.

Insulin was the first protein to be sequenced (in 1955), and it became the first human protein to be manufactured through human recombinant technology. It was introduced into clinical practice in 1982 as synthetic “human” insulin, with the advantage of being less allergenic than animal insulin preparations. Human insulin eventually replaced all of the animal insulin preparations in the US market.

The pursuit of tight glycemic control as an effective strategy to prevent the chronic and devastating complications of the disease was confirmed in 1993 by publication of the Diabetes Control and Complications Trial (DCCT), which undeniably established the relationship between normalization of glycemia and prevention of microvascular complications in patients with type 1 diabetes.¹ The UK Prospective Diabetes Study, demonstrating a similar relationship in type 2 diabetes, was soon to follow.² In both trials, the follow-up observation periods further underscored the importance of early glycemic control by showing both sustained reductions in microvascular complications (retinopathy, nephropathy, and neuropathy) and statistically significant decreases in the risk of a cardiovascular event.^3,4 Of note, it was the introduction in clinical practice of safer and more user-friendly insulin options that made these gains in glycemic control possible.

With the publication of the DCCT results,¹ physio­logic insulin replacement became the therapeutic standard in patients with advanced insulin deficiency, demonstrating that lowering hemoglobin A1c (HbA1c) and mitigating glycemic variability translated into microvascular risk reduction. The use of longer-acting insulin preparations, such as ultralente insulin, and the delivery of the basal component through continuous subcutaneous (SC) insulin infusion using an insulin pump further facilitated achievement of near-normal glycemia.

Insulin products continue to be refined and new formulations and molecular entities developed (Table 1). The following sections review the current insulin products, their pharmacologic profiles, and their clinical roles in diabetes practice.

INSULIN ANALOGUES

In 1996, the first short-acting insulin analogue (or insulin-receptor ligand), lispro, was brought to market. In lispro, the penultimate lysine and proline amino acids on the end of the C-terminal of the beta-chain of human insulin are reversed, facilitating faster absorption of the insulin through the greater availability of insulin monomers following SC depot injection.

The three short-acting insulin analogues—lispro, aspart, and glulisine—have similar pharmacokinetic and pharmacodynamic properties, with earlier onset and peak of biologic action, and shorter duration of activity than regular insulin. Potentially, these characteristics should translate into greater administration flexibility (patients can inject anywhere from 20 minutes before to 20 minutes after the start of the meal), better control of postprandial hyperglycemia, and less risk of late prandial hypoglycemia (3 to 6 hours after the meal). In a meta-analysis comparing short-acting analogues with human regular insulin, the most relevant difference reported was a lower risk of severe hypoglycemia with the analogue preparations⁵ (Table 2). There might be an advantage with regards to bedtime and overnight hypoglycemia when using short-acting analogues, especially if a protaminated insulin is used for overnight basal coverage.⁶

While short-acting analogues have been approved for administration following a meal, postprandial control is clearly better if these preparations are injected prior to the meal, ideally 15 to 20 minutes before, to allow time to enter the circulation.⁷ Additionally, the pharmacokinetics and biologic activity of short-acting insulin analogues appear to be very different when administered to obese, insulin-resistant patients with type 2 diabetes, in whom the onset of action is delayed and the biologic activity considerably reduced.⁸

INHALED INSULIN

Data from Afrezza (insulin human) inhalation powder [package insert]. Danbury, CT: MannKind Corp; 2014.

A recent entry into the short-acting insulin marketplace—Technosphere oral-inhaled insulin (Afrezza)—was US Food and Drug Administration (FDA)-approved in 2014. Inhaled insulin has low bioavailability but is absorbed much more rapidly into the circulation than the current short-acting insulin analogues and has a shorter duration of biologic activity. However, the pharmacodynamics of inhaled insulin, when compared with insulin lispro, show only a slightly faster onset of action and a lower peak of biologic activity⁹ (Figure 1). Studies comparing the efficacy and safety of inhaled insulin with short-acting analogues or premix insulin have demonstrated equivalent or less effective blood glucose-lowering effect and equivalent or lower risk of hypoglycemia.¹⁰ For example, in trials of aspart insulin in patients with type 1 diabetes, inhaled insulin had statistically less reduction in HbA1c; in only one of the two trials did it show less hypoglycemia risk. Another trial comparing inhaled insulin plus basal insulin to premix aspart 70/30 showed equivalent HbA1c reductions, but less hypoglycemia with inhaled insulin.¹⁰

Inhaled insulin should not be used by smokers, patients with chronic lung disease (such as asthma and chronic obstructive pulmonary disease), and those with acute episodes of bronchospasm. In patients who have a history of or are at risk for lung cancer, the benefits of using inhaled insulin need to be carefully weighed against the potential risks, especially given the increase in lung cancer events in smokers that was observed with the prior inhaled-insulin preparation Exubera.¹¹ Baseline and follow-up spirometry needs to be implemented for those using inhaled insulin to exclude clinically significant changes in forced expiratory volume in 1 second. Dosing of inhaled technosphere insulin is done via single-use cartridges of 4-, 8-, or 12-unit composition, making titration of smaller insulin increments more of a challenge. Patient reported outcomes in trials of inhaled insulin report variable effect (equivalent or favorable) on diabetes worries, health-related quality of life, or perceptions of insulin therapy, satisfaction, or preference.^12,13

CONCENTRATED INSULIN

Concentrated insulin preparations have been available in clinical practice for many years and have been implemented with variable success. For example, Humulin R U-500 is a concentrated human regular insulin product (five times more concentrated than U-100) that has been used in patients requiring consistently high daily doses of insulin (usually > 200 U/day). Nonrandomized studies have shown significant improvement in glycemic control comparing pre- and post-intervention periods in patients switched from U-100 prandial insulin preparations to U-500 regular insulin.¹⁴ Given the slight differences in pharmacodynamic profiles between regular U-100 and U-500 insulin preparations,¹⁵ a randomized controlled trial comparing a U-500 insulin strategy with other currently available alternatives in very insulin-resistant patients will be needed to draw objective conclusions regarding the efficacy and safety of this concentrated insulin preparation.

For patients and providers who opt for a trial of regular U-500 insulin, a number of issues need to be considered to mitigate risks and optimize benefits of using this concentrated insulin. First and foremost is the frequent confusion in the communication between provider, pharmacy, and patient regarding the correct insulin dose to be administered. Because regular U-500 insulin is administered with U-100 insulin syringes, a 1-unit measure of U-500 corresponds to a 5-unit delivery of regular insulin.

To minimize confusion, regular U-500 prescriptions should be made out in volume rather than units, but this difference must be clearly explained to patients to avoid overdosing. For example, 0.01 mL of U-500 equates to 5 units of insulin, but it corresponds to the 1-unit mark of the standard U-100 insulin syringe. Newer concentrated insulin preparations on the market have avoided this confusion by providing measured doses in an insulin pen delivery system. For example, insulin lispro U-200 (Humalog U-200), a twofold concentration of insulin lispro U-100 with similar pharmacodynamics, is only available in a prefilled pen. Using insulin pen technology, a 1-unit dose of insulin actually corresponds to 1 unit of insulin, thereby removing any possible confusion regarding the prescription or administration of the correct insulin dose. Insulin lispro U-200 offers the convenience of holding more insulin per pen; it contains 600 units of insulin per pen compared with 300 units in the lispro U-100 pen.

BASAL INSULIN

Currently available basal insulin preparations include insulin NPH (Humulin N, Novolin N), insulin glargine U-100 (Lantus), insulin detemir (Levemir), and the 2015 FDA-approved formulations insulin glargine U-300 (Toujeo) and insulin degludec (Tresiba). The basal analogues introduced in the year 2000 with glargine U-100 were meant to fill the void left when the long-acting insulin ultralente animal preparations were pulled from the market in the early 1990s. The basal analogues have a longer duration of action than insulin NPH and, more importantly, have more stable and consistent biologic activity over a 24-hour period, resulting in more predictable glycemic levels and a lower risk of hypoglycemia.^16–18

Three insulin analogue preparations—glargine U-300 and degludec (both FDA-approved) and pegylated lispro (currently in phase 3 trials)—have demonstrated longer protraction of biologic activity than glargine U-100, considered the current technical standard for basal insulin replacement. These three “second-generation” basal insulin analogues have pharmacodynamic activity that extends beyond 24 hours. When compared with glargine U-100 insulin, they exhibited fewer pronounced peaks of biologic activity and less pharmacokinetic variability, with similar glycemic control (as determined by HbA1c) but with an even lower risk of hypoglycemia, especially nocturnal hypoglycemia.^19–21

The extended biologic activity raises concern for potential insulin stacking and subsequent hypoglycemia, which should be easily mitigated by restricting basal insulin dose adjustments to no more frequently than every 3 to 4 days, which corresponds to the time needed for these preparations to reach 90% or more of their effective steady state²² (Figure 2). Indeed, most of the clinical trials comparing these basal insulin preparations with glargine U-100 show a lower risk of hypoglycemia when basal dose adjustments are carried out weekly and no more frequently than every 3 days.²³

Insulin glargine U-300 is essentially a threefold concentrated preparation of insulin glargine U-100 that results in a two-thirds volume reduction and a one-half reduction in depot surface following SC administration. The reduced depot surface area is presumed to account for much of the protracted absorption of glargine U-300 from the SC tissues. The metabolism and elimination of glargine U-300 is similar to that of the original compound, with formation of two active metabolites: M1 (the principal active moiety) and M2. Biologic steady state is achieved after 4 to 5 days of once-daily injections.²⁴

When compared with glargine U-100 in patients with type 1 diabetes, insulin glargine U-300 at doses of 0.4 U/kg produced more stable insulin concentrations and glucose-lowering effect with a longer duration of action at steady state, as reflected by tight glucose control being maintained for about 5 hours longer (median of 30 hours).²⁵ A meta-analysis of the EDITION I to III clinical trials in patients with type 2 diabetes at various stages of treatment found similar glucose-lowering effects for glargine U-300 compared with glargine U-100 but a lower rate of nonsevere hypoglycemia.²⁰ Of note was the need for 10% to 15% more units of insulin for glargine U-300 in these clinical trials. Insulin glargine U-300 is available only in a 1.5 mL disposable prefilled pen, which contains 450 units of insulin. Because the dose counter on the pen window corresponds to the actual number of units of insulin to be injected, no dose recalculation is required by the patient or provider.

Insulin degludec is another ultra-long-acting basal insulin analogue with a half-life at steady state of greater than 25 hours.²⁶ In comparison, the half-life of insulin glargine U-100 in that same study was reported as 12.1 hours. Further, insulin degludec exhibited flatter and more stable biologic activity, more evenly distributed over the course of a 24-hour period than insulin glargine U-100. The protraction mechanism is based on the formation of long strings of multihexamers, facilitated by a 16-carbon fatty acid chain linked via a glutamic acid spacer to the terminal end of the B-chain of the insulin molecule.²⁷ In studies of patients with type 2 diabetes at various stages of treatment, insulin degludec also demonstrated lower risk of nonsevere hypoglycemia for an equivalent level of HbA1c control achieved.¹⁹

The flexibility of administration time for an ultra-long-acting insulin preparation such as degludec was tested by asking patients to alternate the injection of degludec between morning and evening, in effect creating administration intervals of up to 8 to 40 hours.²⁸ Even within such drastic parameters, the efficacy and safety of insulin degludec were maintained when compared with insulin glargine U-100 injected at the same time of the day every day.

Because of an increase in major adverse cardiovascular events in phase 3 trials, degludec is undergoing a cardiovascular safety trial in patients with type 2 diabetes. The DEVOTE trial, which started in October 2013, will include 7,500 patients and will continue for up to 5 years. Interim results have recently been submitted to the FDA resulting in conditional approval of degludec in the US (Clinical Trials.gov Registration: NCT01959529). Degludec is available in disposable pen or cartridge format in U-100 and U-200 formulations.

COST

These new insulin preparations have introduced clinical options that have efficacy similar to that of available insulin products but, for the most part, have advantages of safety (less risk of nonsevere hypoglycemia) and patient convenience (flexibility in timing of insulin dose administration). While the latter is presumed to improve patient adherence, this has yet to be confirmed. Compared with synthetic human insulin preparations (regular insulin, NPH, and premix 70/30 insulin), which can be obtained in certain pharmacies at a discount (usually around 3 cents per unit of insulin), the currently available insulin analogues are considerably more expensive (around 16 to 27 cents per unit of insulin).

Within the guidelines for initiation and intensification of the insulin regimen using basal insulin formulations, the clinician will need to balance the potential benefits and current costs for the treatment of the individual patient. Clearly, as patients with diabetes are brought closer to their glycemic goals with insulin options, they stand to increasingly bene­fit from formulations that provide more consistent glycemic response and less risk of hypoglycemia. For those who are unable to afford the higher costs, especially if their glycemic control is far from the desired target, the use of synthetic human insulin formulations may be entirely appropriate. In this era of individualized care and prescriptions, clinicians have a range of insulin treatment options that will facilitate patients reaching appropriate goals.

The first isolation and successful extraction of insulin in 1921 opened an important chapter in the management of diabetes, especially for patients with profound insulin deficiency. At that time, a 14-year-old patient who was dying from type 1 diabetes received the first insulin injection—a canine pancreatic extract. It was a lifesaving treatment. Within a few months of insulin administration, the patient regained weight and health and went on to live another 13 years before succumbing to pneumonia and chronic complications of hyperglycemia.

While the introduction of regular insulin from animal extracts provided lifesaving therapy for patients with type 1 diabetes, it was the introduction of protaminated insulin in 1946 that provided more extended “basal” coverage to taper some of the large glycemic fluctuations that occurred with the administration of regular insulin two to three times daily. The use of a split-mix approach with twice-daily administration of a combination of regular insulin plus either insulin neutral protamine Hagedorn (NPH) or insulin lente provided overall better control with fewer episodes of hypoglycemia or severe hyperglycemia.

Insulin was the first protein to be sequenced (in 1955), and it became the first human protein to be manufactured through human recombinant technology. It was introduced into clinical practice in 1982 as synthetic “human” insulin, with the advantage of being less allergenic than animal insulin preparations. Human insulin eventually replaced all of the animal insulin preparations in the US market.

The pursuit of tight glycemic control as an effective strategy to prevent the chronic and devastating complications of the disease was confirmed in 1993 by publication of the Diabetes Control and Complications Trial (DCCT), which undeniably established the relationship between normalization of glycemia and prevention of microvascular complications in patients with type 1 diabetes.¹ The UK Prospective Diabetes Study, demonstrating a similar relationship in type 2 diabetes, was soon to follow.² In both trials, the follow-up observation periods further underscored the importance of early glycemic control by showing both sustained reductions in microvascular complications (retinopathy, nephropathy, and neuropathy) and statistically significant decreases in the risk of a cardiovascular event.^3,4 Of note, it was the introduction in clinical practice of safer and more user-friendly insulin options that made these gains in glycemic control possible.

With the publication of the DCCT results,¹ physio­logic insulin replacement became the therapeutic standard in patients with advanced insulin deficiency, demonstrating that lowering hemoglobin A1c (HbA1c) and mitigating glycemic variability translated into microvascular risk reduction. The use of longer-acting insulin preparations, such as ultralente insulin, and the delivery of the basal component through continuous subcutaneous (SC) insulin infusion using an insulin pump further facilitated achievement of near-normal glycemia.

Insulin products continue to be refined and new formulations and molecular entities developed (Table 1). The following sections review the current insulin products, their pharmacologic profiles, and their clinical roles in diabetes practice.

INSULIN ANALOGUES

In 1996, the first short-acting insulin analogue (or insulin-receptor ligand), lispro, was brought to market. In lispro, the penultimate lysine and proline amino acids on the end of the C-terminal of the beta-chain of human insulin are reversed, facilitating faster absorption of the insulin through the greater availability of insulin monomers following SC depot injection.

The three short-acting insulin analogues—lispro, aspart, and glulisine—have similar pharmacokinetic and pharmacodynamic properties, with earlier onset and peak of biologic action, and shorter duration of activity than regular insulin. Potentially, these characteristics should translate into greater administration flexibility (patients can inject anywhere from 20 minutes before to 20 minutes after the start of the meal), better control of postprandial hyperglycemia, and less risk of late prandial hypoglycemia (3 to 6 hours after the meal). In a meta-analysis comparing short-acting analogues with human regular insulin, the most relevant difference reported was a lower risk of severe hypoglycemia with the analogue preparations⁵ (Table 2). There might be an advantage with regards to bedtime and overnight hypoglycemia when using short-acting analogues, especially if a protaminated insulin is used for overnight basal coverage.⁶

While short-acting analogues have been approved for administration following a meal, postprandial control is clearly better if these preparations are injected prior to the meal, ideally 15 to 20 minutes before, to allow time to enter the circulation.⁷ Additionally, the pharmacokinetics and biologic activity of short-acting insulin analogues appear to be very different when administered to obese, insulin-resistant patients with type 2 diabetes, in whom the onset of action is delayed and the biologic activity considerably reduced.⁸

INHALED INSULIN

Data from Afrezza (insulin human) inhalation powder [package insert]. Danbury, CT: MannKind Corp; 2014.

A recent entry into the short-acting insulin marketplace—Technosphere oral-inhaled insulin (Afrezza)—was US Food and Drug Administration (FDA)-approved in 2014. Inhaled insulin has low bioavailability but is absorbed much more rapidly into the circulation than the current short-acting insulin analogues and has a shorter duration of biologic activity. However, the pharmacodynamics of inhaled insulin, when compared with insulin lispro, show only a slightly faster onset of action and a lower peak of biologic activity⁹ (Figure 1). Studies comparing the efficacy and safety of inhaled insulin with short-acting analogues or premix insulin have demonstrated equivalent or less effective blood glucose-lowering effect and equivalent or lower risk of hypoglycemia.¹⁰ For example, in trials of aspart insulin in patients with type 1 diabetes, inhaled insulin had statistically less reduction in HbA1c; in only one of the two trials did it show less hypoglycemia risk. Another trial comparing inhaled insulin plus basal insulin to premix aspart 70/30 showed equivalent HbA1c reductions, but less hypoglycemia with inhaled insulin.¹⁰

Inhaled insulin should not be used by smokers, patients with chronic lung disease (such as asthma and chronic obstructive pulmonary disease), and those with acute episodes of bronchospasm. In patients who have a history of or are at risk for lung cancer, the benefits of using inhaled insulin need to be carefully weighed against the potential risks, especially given the increase in lung cancer events in smokers that was observed with the prior inhaled-insulin preparation Exubera.¹¹ Baseline and follow-up spirometry needs to be implemented for those using inhaled insulin to exclude clinically significant changes in forced expiratory volume in 1 second. Dosing of inhaled technosphere insulin is done via single-use cartridges of 4-, 8-, or 12-unit composition, making titration of smaller insulin increments more of a challenge. Patient reported outcomes in trials of inhaled insulin report variable effect (equivalent or favorable) on diabetes worries, health-related quality of life, or perceptions of insulin therapy, satisfaction, or preference.^12,13

CONCENTRATED INSULIN

Concentrated insulin preparations have been available in clinical practice for many years and have been implemented with variable success. For example, Humulin R U-500 is a concentrated human regular insulin product (five times more concentrated than U-100) that has been used in patients requiring consistently high daily doses of insulin (usually > 200 U/day). Nonrandomized studies have shown significant improvement in glycemic control comparing pre- and post-intervention periods in patients switched from U-100 prandial insulin preparations to U-500 regular insulin.¹⁴ Given the slight differences in pharmacodynamic profiles between regular U-100 and U-500 insulin preparations,¹⁵ a randomized controlled trial comparing a U-500 insulin strategy with other currently available alternatives in very insulin-resistant patients will be needed to draw objective conclusions regarding the efficacy and safety of this concentrated insulin preparation.

For patients and providers who opt for a trial of regular U-500 insulin, a number of issues need to be considered to mitigate risks and optimize benefits of using this concentrated insulin. First and foremost is the frequent confusion in the communication between provider, pharmacy, and patient regarding the correct insulin dose to be administered. Because regular U-500 insulin is administered with U-100 insulin syringes, a 1-unit measure of U-500 corresponds to a 5-unit delivery of regular insulin.

To minimize confusion, regular U-500 prescriptions should be made out in volume rather than units, but this difference must be clearly explained to patients to avoid overdosing. For example, 0.01 mL of U-500 equates to 5 units of insulin, but it corresponds to the 1-unit mark of the standard U-100 insulin syringe. Newer concentrated insulin preparations on the market have avoided this confusion by providing measured doses in an insulin pen delivery system. For example, insulin lispro U-200 (Humalog U-200), a twofold concentration of insulin lispro U-100 with similar pharmacodynamics, is only available in a prefilled pen. Using insulin pen technology, a 1-unit dose of insulin actually corresponds to 1 unit of insulin, thereby removing any possible confusion regarding the prescription or administration of the correct insulin dose. Insulin lispro U-200 offers the convenience of holding more insulin per pen; it contains 600 units of insulin per pen compared with 300 units in the lispro U-100 pen.

BASAL INSULIN

Currently available basal insulin preparations include insulin NPH (Humulin N, Novolin N), insulin glargine U-100 (Lantus), insulin detemir (Levemir), and the 2015 FDA-approved formulations insulin glargine U-300 (Toujeo) and insulin degludec (Tresiba). The basal analogues introduced in the year 2000 with glargine U-100 were meant to fill the void left when the long-acting insulin ultralente animal preparations were pulled from the market in the early 1990s. The basal analogues have a longer duration of action than insulin NPH and, more importantly, have more stable and consistent biologic activity over a 24-hour period, resulting in more predictable glycemic levels and a lower risk of hypoglycemia.^16–18

Three insulin analogue preparations—glargine U-300 and degludec (both FDA-approved) and pegylated lispro (currently in phase 3 trials)—have demonstrated longer protraction of biologic activity than glargine U-100, considered the current technical standard for basal insulin replacement. These three “second-generation” basal insulin analogues have pharmacodynamic activity that extends beyond 24 hours. When compared with glargine U-100 insulin, they exhibited fewer pronounced peaks of biologic activity and less pharmacokinetic variability, with similar glycemic control (as determined by HbA1c) but with an even lower risk of hypoglycemia, especially nocturnal hypoglycemia.^19–21

The extended biologic activity raises concern for potential insulin stacking and subsequent hypoglycemia, which should be easily mitigated by restricting basal insulin dose adjustments to no more frequently than every 3 to 4 days, which corresponds to the time needed for these preparations to reach 90% or more of their effective steady state²² (Figure 2). Indeed, most of the clinical trials comparing these basal insulin preparations with glargine U-100 show a lower risk of hypoglycemia when basal dose adjustments are carried out weekly and no more frequently than every 3 days.²³

Insulin glargine U-300 is essentially a threefold concentrated preparation of insulin glargine U-100 that results in a two-thirds volume reduction and a one-half reduction in depot surface following SC administration. The reduced depot surface area is presumed to account for much of the protracted absorption of glargine U-300 from the SC tissues. The metabolism and elimination of glargine U-300 is similar to that of the original compound, with formation of two active metabolites: M1 (the principal active moiety) and M2. Biologic steady state is achieved after 4 to 5 days of once-daily injections.²⁴

When compared with glargine U-100 in patients with type 1 diabetes, insulin glargine U-300 at doses of 0.4 U/kg produced more stable insulin concentrations and glucose-lowering effect with a longer duration of action at steady state, as reflected by tight glucose control being maintained for about 5 hours longer (median of 30 hours).²⁵ A meta-analysis of the EDITION I to III clinical trials in patients with type 2 diabetes at various stages of treatment found similar glucose-lowering effects for glargine U-300 compared with glargine U-100 but a lower rate of nonsevere hypoglycemia.²⁰ Of note was the need for 10% to 15% more units of insulin for glargine U-300 in these clinical trials. Insulin glargine U-300 is available only in a 1.5 mL disposable prefilled pen, which contains 450 units of insulin. Because the dose counter on the pen window corresponds to the actual number of units of insulin to be injected, no dose recalculation is required by the patient or provider.

Insulin degludec is another ultra-long-acting basal insulin analogue with a half-life at steady state of greater than 25 hours.²⁶ In comparison, the half-life of insulin glargine U-100 in that same study was reported as 12.1 hours. Further, insulin degludec exhibited flatter and more stable biologic activity, more evenly distributed over the course of a 24-hour period than insulin glargine U-100. The protraction mechanism is based on the formation of long strings of multihexamers, facilitated by a 16-carbon fatty acid chain linked via a glutamic acid spacer to the terminal end of the B-chain of the insulin molecule.²⁷ In studies of patients with type 2 diabetes at various stages of treatment, insulin degludec also demonstrated lower risk of nonsevere hypoglycemia for an equivalent level of HbA1c control achieved.¹⁹

The flexibility of administration time for an ultra-long-acting insulin preparation such as degludec was tested by asking patients to alternate the injection of degludec between morning and evening, in effect creating administration intervals of up to 8 to 40 hours.²⁸ Even within such drastic parameters, the efficacy and safety of insulin degludec were maintained when compared with insulin glargine U-100 injected at the same time of the day every day.

Because of an increase in major adverse cardiovascular events in phase 3 trials, degludec is undergoing a cardiovascular safety trial in patients with type 2 diabetes. The DEVOTE trial, which started in October 2013, will include 7,500 patients and will continue for up to 5 years. Interim results have recently been submitted to the FDA resulting in conditional approval of degludec in the US (Clinical Trials.gov Registration: NCT01959529). Degludec is available in disposable pen or cartridge format in U-100 and U-200 formulations.

COST

These new insulin preparations have introduced clinical options that have efficacy similar to that of available insulin products but, for the most part, have advantages of safety (less risk of nonsevere hypoglycemia) and patient convenience (flexibility in timing of insulin dose administration). While the latter is presumed to improve patient adherence, this has yet to be confirmed. Compared with synthetic human insulin preparations (regular insulin, NPH, and premix 70/30 insulin), which can be obtained in certain pharmacies at a discount (usually around 3 cents per unit of insulin), the currently available insulin analogues are considerably more expensive (around 16 to 27 cents per unit of insulin).

Within the guidelines for initiation and intensification of the insulin regimen using basal insulin formulations, the clinician will need to balance the potential benefits and current costs for the treatment of the individual patient. Clearly, as patients with diabetes are brought closer to their glycemic goals with insulin options, they stand to increasingly bene­fit from formulations that provide more consistent glycemic response and less risk of hypoglycemia. For those who are unable to afford the higher costs, especially if their glycemic control is far from the desired target, the use of synthetic human insulin formulations may be entirely appropriate. In this era of individualized care and prescriptions, clinicians have a range of insulin treatment options that will facilitate patients reaching appropriate goals.

Hyperglycemia in hospitalized patients, with or without diabetes, is associated with adverse outcomes including increased rates of infection and mortality and longer hospital length of stay.^1–3 The rates of complications and mortality are even higher in hyperglycemic patients without a history of diabetes than in those with diabetes.^1,2 Randomized clinical trials in critically ill and noncritically ill hyperglycemic patients demonstrate that improved glycemic control can reduce hospital complications, systemic infections, and hospitalization cost.^4–6 However, intensive glycemic therapy is associated with increased risk of hypoglycemia, which is independently associated with increased morbidity and mortality in hospitalized patients. The concern about hypoglycemia has led to revised blood glucose target recommendations from professional organizations and a search for alternative treatment options.

This manuscript provides a review of updated recommendations for the management of inpatients with hyperglycemia in the critical care and general medical and surgical settings.

HYPERGLYCEMIA IN CRITICAL CARE SETTINGS

A substantial body of evidence links hyperglycemia in critically ill patients to higher rates of hospital complications, longer hospital stay, higher healthcare resource utilization, and greater hospital mortality.^7,8 Although evidence from several cohort studies and randomized clinical trials suggests that tight glucose control can reduce hospital complications and mortality,^9,10 this target has been difficult to achieve without increasing the risk of severe hypoglycemia. In addition, data from trials using intense glycemic control in patients in the intensive care unit (ICU) have failed to show a significant improvement in mortality and, in some instances, showed increased mortality risk associated with the therapy.^11,12

The recommended target glucose levels are 140 to 180 mg/dL for most ICU patients.¹³ In agreement with this, the recent GLUCO-CABG trial reported no significant differences in the composite end points of complications and death between an intensive glucose target of 100 to 140 mg/dL and a conservative target of 141 to 180 mg/dL after cardiac surgery.¹⁴

HYPERGLYCEMIA IN NONCRITICAL CARE SETTINGS

In general medical and surgical patients, a strong association has been reported between hyperglycemia and prolonged hospital stay, infection, and disability after hospital discharge.^1,15,16 For example, the risk of postoperative infections in patients undergoing general surgery was estimated to increase by 30% for every 40 mg/dL rise in glucose over normo­glycemia (< 110 mg/dL).¹⁶ In general, appropriate glycemic control to maintain recommended glycemic levels in noncritically ill patients can reduce the risks and improve outcomes. 

HYPOGLYCEMIA INCIDENCE

Hypoglycemia, defined as glucose less than 70 mg/dL, is a common complication of hyperglycemia treatment.¹⁷ Severe hypoglycemia is defined as glucose less than 40 mg/dL.¹⁸ The incidence of hypoglycemia in ICU trials ranged between 5% and 28%, depending on the intensity of glycemic control,¹⁹ and between 1% and 33% in non-ICU trials using subcutaneous (SC) insulin therapy.²⁰ The most important hypoglycemia risk factors include older age, kidney failure, change in nutritional intake, interruption of glucose monitoring, previous insulin therapy, and failure to adjust therapy when glucose is trending down or steroid therapy is being tapered.^21,22

In hospitalized patients with diabetes, hypoglycemia has been associated with poor outcomes, including a 66% increased risk of death within 1 year and 2.8 days longer hospital stay compared with patients without hypoglycemia.²³ Hypoglycemia also has been associated with prolonged QT interval, ischemic electro­cardiogram changes, angina, arrhythmias, and sudden death in patients with type 1 diabetes.²⁴ Despite these observations, other studies have reported that the increased in-hospital mortality rate is limited to patients with spontaneous hypoglycemia rather than drug-associated hypoglycemia,²⁵ raising the possibility that hypoglycemia may represent a marker of disease burden rather than be a direct cause of death.

INPATIENT ASSESSMENT OF HYPERGLYCEMIA

Clinical guidelines recommend glucose measurement in all patients admitted to the hospital.^13,26 Patients with hyperglycemia (glucose > 140 mg/dL) and patients with a history of diabetes should undergo bedside point-of-care glucose testing before meals and at bedtime. Premeal testing should be done close to the time of the meal tray delivery and no longer than 1 hour before meals. For patients taking nothing by mouth or receiving continuous enteral nutrition, point-of-care testing is recommended every 4 to 6 hours.

Hemoglobin A1c (HbA1c) should be measured in patients with hyperglycemia and in those with diabetes if it has not been performed in the preceding 2 to 3 months. In hyperglycemic patients without a history of diabetes, an HbA1c of 6.5% or greater suggests that diabetes preceded hospitalization. In patients with diabetes, the HbA1c can help assess glycemic control prior to admission and tailor the treatment regimen at discharge.^13,26

TARGET GLUCOSE LEVELS

Glycemic targets recommended by several organizations are shown in Table 1. For critically ill patients, most societies recommend glucose targets below 180 mg/dL, with the lower limit being anywhere from 110 to less than 150 mg/dL.

For patients in non-ICU settings, the Endocrine Society²⁶ and the American Diabetes Association/American Association of Endocrinologists¹³ practice guidelines recommend premeal glucose levels below 140 mg/dL, and below 180 mg/dL if checked randomly. Higher glucose ranges (< 200 mg/dL) may be acceptable in terminally ill patients or in patients with severe comorbidities.²⁶ Guidelines from the Joint British Diabetes Societies recommend targeting glucose levels between 108 and 180 mg/dL with an acceptable range of between 72 and 216 mg/dL.²⁷

INPATIENT MANAGEMENT OF HYPERGLYCEMIA AND DIABETES

Insulin regimens in critical care settings

Insulin administration is the preferred way to control hyperglycemia in hospitalized patients. In critically ill patients, such as those with hypotension requiring pressor support, hyperglycemic crises, sepsis, or shock, insulin is best given via continuous intravenous (IV) infusion. The short half-life of IV insulin (< 15 minutes) allows flexibility in adjusting the infusion rate in the event of unpredicted changes in nutrition or the patient’s health. If the glucose level rises above 180 mg/dL, IV insulin infusion should be started to maintain levels below 180 mg/dL.^13,26,28,29

A variety of infusion protocols have been shown to be effective in achieving glycemic control with a low rate of hypoglycemia. The ideal protocol should allow flexible rate adjustment taking into account current and previous glucose values as well as changes in infusion rate. Hourly glucose measurements until stable glycemic control is established, followed by point-of-care testing every 1 to 2 hours, is needed to assess response to therapy and prevent hypoglycemia.

Insulin regimens in noncritical care settings

For most patients in a general, non-ICU setting, SC insulin therapy with basal insulin administered once or twice daily, alone or in combination with prandial insulin, is effective and safe.¹³ Inhaled insulin is approved by the US Food and Drug Administration, but its use in the hospital has not been studied. The use of sliding-scale insulin is not acceptable as the single regimen in patients with diabetes, as it results in undesirable hypoglycemia and hyperglycemia.³⁰Figure 1 presents an algorithm for selecting initial insulin treatment for patients with type 2 diabetes in the non-ICU setting.

Basal insulin prevents hyperglycemia during fasting states. Basal insulin is usually given as a once- or twice-daily long-acting insulin, such as glargine and detemir insulin. On occasion, twice-daily intermediate-acting insulin (neutral protamine Hagedorn; NPH) is used as a basal insulin.

Prandial insulin, also referred to as nutritional or bolus insulin, is given before meals as rapid-acting insulin (aspart, lispro, or glulisine) or short-acting insulin (regular) to prevent postmeal hyperglycemia. Rapid-acting insulin is preferred to regular insulin because of the faster onset and shorter duration of action, which may reduce the risk of hypoglycemia.

Correction or supplemental insulin is given to correct hyperglycemia when the glucose is above the goal. The same formulation is given together with prandial insulin.

Total daily dose of insulin is a measure that comprises basal and prandial insulin Figure 1 lists the recommended total daily dose for different clinical situations and patient populations.

Basal-bolus insulin usually refers to a regimen of long-acting basal insulin plus prandial insulin. In patients with adequate oral intake, the basal-bolus approach is preferred. The RABBIT 2 trial reported that basal-bolus regimens resulted in greater improvement in glucose control than sliding-scale regimens (correction insulin alone without basal or prandial components) in general medicine patients with type 2 diabetes.³² In general surgery patients, basal-bolus regimens significantly improved glucose control and reduced the numbers of post­operative complications, primarily wound infections compared with sliding-scale regimens.⁴

Multiple doses of NPH and regular insulin were compared with basal-bolus treatment with long-acting and rapid-acting insulin in two controlled trials in medical patients with type 2 diabetes.^20,33 Both studies reported that treatment with NPH and regular insulin resulted in similar improvements in glycemic control and no difference in the rate of hypoglycemic events or in hospital length of stay, compared with basal-bolus insulin. Because NPH has a peak of action approximately 8 to 12 hours after injection, there is a risk of hypoglycemia in patients with poor oral intake.

In hospitalized patients who have reduced total caloric intake due to lack of appetite, acute illness, medical procedures, or surgical interventions, the Basal Plus trial³⁴ reported that a single daily dose of glargine plus correction doses of rapid-acting insulin resulted in similar improvement in glycemic control and no difference in the frequency of hypoglycemia compared with a standard basal-bolus regimen. These results indicate that the basal-plus-correction regimen may be preferred for patients with poor or no oral intake, whereas an insulin regimen with basal, nutritional (basal-bolus), and correction components is preferred for patients with good nutritional intake.³⁵

SC insulin dosing refers to insulin doses administered subcutaneously calculated based either on weight or on home insulin doses. For insulin-naive patients, the starting total daily dose of insulin can usually be computed as 0.4 to 0.5 U/kg/day. Higher starting doses are associated with greater odds of hypoglycemia than doses lower than 0.2 U/kg/day.³⁶ In elderly patients and those with impaired renal function, lower initial daily doses (≤ 0.3 U/kg) may reduce the risk of hypoglycemia.²⁶

In patients treated with insulin prior to admission, the total daily insulin dose at home can be given as half long-acting basal insulin and half prandial insulin. The dose can be reduced by 20% to 25% to prevent hypoglycemia, particularly in those with poor or uncertain caloric intake.³¹

Noninsulin therapies

The use of oral antidiabetic agents is generally not recommended in hospitalized patients due to the limited data available on their safety and efficacy, frequent contraindications, risk of hypoglycemia, and slow onset of action that may preclude achieving rapid glycemic control and daily dose adjustments. Table 3 lists the pros and cons of these agents in hospitalized patients.

The safety and efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the management of inpatient hyperglycemia was evaluated in a randomized pilot study in patients with type 2 diabetes treated at home with diet, oral antidiabetic agents, or a low daily insulin dose (≤ 0.4 U/kg/day).³⁷ Patients were randomized to one of two treatments:

• Sitagliptin alone or with low-dose glargine insulin
• Basal-bolus insulin regimen plus supplemental doses of insulin lispro.

Both treatment regimens resulted in similar improvement in mean daily glucose concentrations. However, patients admitted to the hospital with glucose levels above 180 mg/dL in the sitagliptin group had higher mean daily glucose levels than patients treated with basal-bolus or sitagliptin plus glargine.

Transitioning from IV to SC insulin

When patients in critical care units are ready to be transferred to a general medical floor, appropriate transition from IV insulin to scheduled SC insulin is needed to prevent rebound hyperglycemia. This is imperative in patients with type 1 diabetes in whom just a few hours without insulin can result in diabetic ketoacidosis.

There are three general ways to calculate the SC insulin dose during the transition period. The first two methods are weight-based and based on the home dose, as previously discussed. The third method is to extrapolate from the IV insulin. A common way is to sum up the total IV insulin dose in the past 6 or 8 hours and multiply by 3 or 4, and then reduce by 20% to achieve the basal insulin dose, presuming the patient had no oral intake on the IV insulin infusion. This last method is preferred in hemodynamically stable patients with stable insulin requirements.

If long-acting insulin is chosen as basal insulin, it should be given 2 to 4 hours before discontinuation of the IV insulin infusion. Intermediate-acting insulin should be given 1 to 2 hours before IV insulin discontinuation.

SPECIFIC SITUATIONS AND POPULATIONS

Type 1 diabetes

Patients with type 1 diabetes have minimal to absent pancreatic beta cell function and rely on the exogenous administration of insulin to maintain glucose homeostasis. They have worse glycemic control and higher rates of acute kidney injury than patients with type 2 diabetes; however, the impact of inpatient glycemic control on clinical outcomes has not been determined in patients with type 1 diabetes. Insulin therapy must provide both basal and nutritional components to achieve the target goals. It is important to ask the patient directly to determine the times and doses of prescribed insulin, medication adherence, recent dietary habits (including changes in appetite), and level of physical activity. This information will be used to guide insulin therapy.

A systematic review of 16 clinical studies reported that patients who possess excellent self-management skills can be suitable for successful inpatient diabetes self-management.³⁸ The American Diabetes Association supports patient self-management of diabetes in the hospital.³⁹ However, the competence and readiness of each patient with type 1 diabetes need to be carefully determined in an individualized manner. Potential candidates for inpatient self-management are those with unaltered mental status, proven proficient outpatient skills (eg, carbohydrate counting, frequent glucose monitoring, strong knowledge related to the management of insulin pump or injection techniques), and who are tolerating oral intake.

Enteral nutrition and tube feeding

Accidental dislodgement of feeding tubes, temporary discontinuation of nutrition due to nausea or for diagnostic testing, and cycling of enteral nutrition with oral intake in patients with an inconsistent appetite pose unique challenges in the hospital. Although it may be tempting to give basal and nutritional requirements to these patients as a single dose of long-acting insulin, this is not recommended. Low-dose basal insulin plus scheduled doses of short-acting (regular) insulin (every 6 hours) or rapid-acting insulin (every 4 hours) with correction insulin is often used. Some providers prefer giving intermediate-acting (NPH) plus short-acting (regular) insulin every 8 hours or every 12 hours.

It is generally accepted that diabetic enteral formulas that are low in carbohydrate and high in monounsaturated fatty acids are preferable to standard high-carbohydrate formulas in hospitalized patients with diabetes. In a meta-analysis, the postprandial rise in glucose was reduced by 20 to 30 mg/dL with the low-carbohydrate high-fat formulations compared with standard formulations.⁴⁰

Parenteral nutrition

The use of parenteral nutrition has been linked to aggravation of hyperglycemia independent of a history of diabetes as well as a higher risk of complications, infections, sepsis, and death.⁴¹ Regular insulin can be added to the parenteral solution at a starting dose of 0.1 U/g of dextrose in nondiabetic patients and at 0.15 U/g of dextrose in patients with diabetes.⁴²

Alternatively, insulin can be given as a continuous IV infusion. Hemodynamically stable patients with mild to moderate hyperglycemia can be managed with basal insulin plus scheduled or as-needed doses of short-acting (regular) insulin every 6 hours. To prevent waste, it is better to underestimate the insulin added to parenteral nutrition so as to avoid having to discontinue it prematurely or add additional glucose.

Glucocorticoids

Glucocorticoids typically raise glucose starting 4 to 6 hours after administration. Low doses of glucocorticoids given in the morning tend to raise the late morning to evening glucose levels without affecting the fasting glucose. In this situation, the patient may be managed on prandial insulin without long-acting basal insulin or with intermediate-acting insulin given in the morning. Higher glucocorticoid doses may raise fasting glucose levels, in which case basal-bolus insulin would be appropriate, with the basal component comprising about 30% and the bolus about 70% of the daily dose.²⁶

Insulin pump

Approximately 400,000 US patients with diabetes use an insulin pump.⁴³ Successful management of inpatient diabetes with the continuation of insulin pump therapy has been previously demonstrated in select patients. Clear hospital policies, procedures, and physicians’ orders with specifics on the type of diet, frequency of point-of-care glucose testing, and insulin doses (ie, basal rates, carbohydrate ratios, and correction formulas) should be in place. An inpatient diabetes specialist should assist with the assessment and management of a patient with an insulin pump.

If pump use is contraindicated (Table 4)⁴⁴ or if inpatient diabetes resources are not available, discontinuation of insulin pump and transition to a basal-bolus insulin regimen (“pump holiday”) may be the safest and most appropriate step. Most patients knowledgeable in insulin pump therapy are able to display in their pump screen the average total daily insulin used for the past few days. Based on this, safe estimations of basal, bolus, and supplemental insulin can be calculated. To avoid severe hyperglycemia or ketoacidosis from lack of basal insulin, it is important to administer the basal insulin component at least 2 hours before disconnecting the insulin pump.

Concentrated insulins

U-500 regular insulin is concentrated insulin that delivers the same amount of units in one-fifth the volume of conventional insulins, which are U-100. Whereas there are 100 units of insulin in 1 mL for conventional insulins, there are 500 units of U-500 regular insulin in 1 mL. Its onset of action is similar to that of regular insulin, and the peak and duration are similar to that of NPH insulin. Concentrated insulin is often administered in the outpatient setting to patients who are insulin resistant and require close to 200 units a day. The U-500 pen device was approved in January 2016 and was projected to be available in April 2016. For now, it can only be procured in the vial form. This causes confusion in its dosing since it is given either with the usual insulin syringes, which are designed for U-100 insulin administration, or a tuberculin syringe, which is not marked in units but in milliliters.

Because of its unique nature and providers’ lack of familiarity with U-500, certain institutions have a policy for its use. In many institutions, the doses are confirmed by pharmacy staff and delivered by pharmacy to the patient’s medication bin predrawn in a tuberculin syringe.⁴⁵ In addition, a study reported that many patients on U-500 at home required significantly lower doses of insulin (average dose of 100 U/day) while hospitalized patients could be managed with conventional insulin formulations.⁴⁵

There are newer concentrated insulins in the market, such as insulin glargine 300 U/mL (Toujeo) and insulin lispro 200 U/mL (Humalog). These insulins, so far, come only in the pen device form and not in vials, obviating the need for dose calculations using a U-100 insulin syringe or tuberculin syringe. The efficacy and safety of these insulin formulations have not been determined in the hospital setting.

Transitioning from home to hospital

Transition to an outpatient setting requires planning and coordination. Although insulin is used in the hospital for most patients with diabetes, many patients do not require insulin after discharge. On the other hand, diabetes regimens sometimes need intensification in other patients. One study showed that patients with acceptable diabetes control (HbA1c < 7.5%) near or on admission could be discharged on their prehospitalization treatment regimen, while those with HbA1c between 7.5% and 9% could be discharged on oral agents plus basal insulin at 50% of the hospital basal dose.⁴⁶ Additionally, patients with an HbA1c of 9% to 10% should be discharged on a basal-bolus regimen or on a combination of oral agents plus basal insulin at 80% of hospital dose, with a reduction in HbA1c seen 12 weeks after discharge.

SUMMARY

Inpatient hyperglycemia is common and is associated with increased risk of hospital complications, higher healthcare resource utilization, and higher rates of in-hospital mortality. In the critically ill, IV insulin is most appropriate, with a starting threshold no higher than 180 mg/dL. Once IV insulin is started, the glucose level should be maintained between 140 and 180 mg/dL.

In noncritically ill patients, a basal-bolus regimen with basal, prandial, and correction components is preferred for patients with good nutritional intake. In contrast, a single dose of long-acting insulin plus correction insulin is preferred for patients with poor or no oral intake. Preliminary data indicate that incretin therapy has the potential to improve glycemic control in patients with mild to moderate hyperglycemia and a low risk of hypoglycemia.

Transition to an outpatient setting requires planning and coordination. Measuring HbA1c at admission is important to assess preadmission glycemic control and to tailor the treatment regimen at discharge. Patients with acceptable diabetes control could be discharged on their prehospitalization treatment regimen. Patients with suboptimal control should have more intensified therapy.

Dr. Umpierrez is supported in part by research grants from the American Diabetes Association (1-14-LLY-36), PHS grant UL1 RR025008 from the Clinical Translational Science Award Program (M01 RR-00039), and grants from the National Institutes of Health and the National Center for Research Resources. He has received unrestricted research support for inpatient studies (at Emory University) from Sanofi, Merck, Novo Nordisk, and Boehringer Ingelheim, and has received consulting fees and/or honoraria for membership on advisory boards from Novo Nordisk, Sanofi, Merck, Boehringer Ingelheim, and Regeneron.
 

Hyperglycemia in hospitalized patients, with or without diabetes, is associated with adverse outcomes including increased rates of infection and mortality and longer hospital length of stay.^1–3 The rates of complications and mortality are even higher in hyperglycemic patients without a history of diabetes than in those with diabetes.^1,2 Randomized clinical trials in critically ill and noncritically ill hyperglycemic patients demonstrate that improved glycemic control can reduce hospital complications, systemic infections, and hospitalization cost.^4–6 However, intensive glycemic therapy is associated with increased risk of hypoglycemia, which is independently associated with increased morbidity and mortality in hospitalized patients. The concern about hypoglycemia has led to revised blood glucose target recommendations from professional organizations and a search for alternative treatment options.

This manuscript provides a review of updated recommendations for the management of inpatients with hyperglycemia in the critical care and general medical and surgical settings.

HYPERGLYCEMIA IN CRITICAL CARE SETTINGS

A substantial body of evidence links hyperglycemia in critically ill patients to higher rates of hospital complications, longer hospital stay, higher healthcare resource utilization, and greater hospital mortality.^7,8 Although evidence from several cohort studies and randomized clinical trials suggests that tight glucose control can reduce hospital complications and mortality,^9,10 this target has been difficult to achieve without increasing the risk of severe hypoglycemia. In addition, data from trials using intense glycemic control in patients in the intensive care unit (ICU) have failed to show a significant improvement in mortality and, in some instances, showed increased mortality risk associated with the therapy.^11,12

The recommended target glucose levels are 140 to 180 mg/dL for most ICU patients.¹³ In agreement with this, the recent GLUCO-CABG trial reported no significant differences in the composite end points of complications and death between an intensive glucose target of 100 to 140 mg/dL and a conservative target of 141 to 180 mg/dL after cardiac surgery.¹⁴

HYPERGLYCEMIA IN NONCRITICAL CARE SETTINGS

In general medical and surgical patients, a strong association has been reported between hyperglycemia and prolonged hospital stay, infection, and disability after hospital discharge.^1,15,16 For example, the risk of postoperative infections in patients undergoing general surgery was estimated to increase by 30% for every 40 mg/dL rise in glucose over normo­glycemia (< 110 mg/dL).¹⁶ In general, appropriate glycemic control to maintain recommended glycemic levels in noncritically ill patients can reduce the risks and improve outcomes. 

HYPOGLYCEMIA INCIDENCE

Hypoglycemia, defined as glucose less than 70 mg/dL, is a common complication of hyperglycemia treatment.¹⁷ Severe hypoglycemia is defined as glucose less than 40 mg/dL.¹⁸ The incidence of hypoglycemia in ICU trials ranged between 5% and 28%, depending on the intensity of glycemic control,¹⁹ and between 1% and 33% in non-ICU trials using subcutaneous (SC) insulin therapy.²⁰ The most important hypoglycemia risk factors include older age, kidney failure, change in nutritional intake, interruption of glucose monitoring, previous insulin therapy, and failure to adjust therapy when glucose is trending down or steroid therapy is being tapered.^21,22

In hospitalized patients with diabetes, hypoglycemia has been associated with poor outcomes, including a 66% increased risk of death within 1 year and 2.8 days longer hospital stay compared with patients without hypoglycemia.²³ Hypoglycemia also has been associated with prolonged QT interval, ischemic electro­cardiogram changes, angina, arrhythmias, and sudden death in patients with type 1 diabetes.²⁴ Despite these observations, other studies have reported that the increased in-hospital mortality rate is limited to patients with spontaneous hypoglycemia rather than drug-associated hypoglycemia,²⁵ raising the possibility that hypoglycemia may represent a marker of disease burden rather than be a direct cause of death.

INPATIENT ASSESSMENT OF HYPERGLYCEMIA

Clinical guidelines recommend glucose measurement in all patients admitted to the hospital.^13,26 Patients with hyperglycemia (glucose > 140 mg/dL) and patients with a history of diabetes should undergo bedside point-of-care glucose testing before meals and at bedtime. Premeal testing should be done close to the time of the meal tray delivery and no longer than 1 hour before meals. For patients taking nothing by mouth or receiving continuous enteral nutrition, point-of-care testing is recommended every 4 to 6 hours.

Hemoglobin A1c (HbA1c) should be measured in patients with hyperglycemia and in those with diabetes if it has not been performed in the preceding 2 to 3 months. In hyperglycemic patients without a history of diabetes, an HbA1c of 6.5% or greater suggests that diabetes preceded hospitalization. In patients with diabetes, the HbA1c can help assess glycemic control prior to admission and tailor the treatment regimen at discharge.^13,26

TARGET GLUCOSE LEVELS

Glycemic targets recommended by several organizations are shown in Table 1. For critically ill patients, most societies recommend glucose targets below 180 mg/dL, with the lower limit being anywhere from 110 to less than 150 mg/dL.

For patients in non-ICU settings, the Endocrine Society²⁶ and the American Diabetes Association/American Association of Endocrinologists¹³ practice guidelines recommend premeal glucose levels below 140 mg/dL, and below 180 mg/dL if checked randomly. Higher glucose ranges (< 200 mg/dL) may be acceptable in terminally ill patients or in patients with severe comorbidities.²⁶ Guidelines from the Joint British Diabetes Societies recommend targeting glucose levels between 108 and 180 mg/dL with an acceptable range of between 72 and 216 mg/dL.²⁷

INPATIENT MANAGEMENT OF HYPERGLYCEMIA AND DIABETES

Insulin regimens in critical care settings

Insulin administration is the preferred way to control hyperglycemia in hospitalized patients. In critically ill patients, such as those with hypotension requiring pressor support, hyperglycemic crises, sepsis, or shock, insulin is best given via continuous intravenous (IV) infusion. The short half-life of IV insulin (< 15 minutes) allows flexibility in adjusting the infusion rate in the event of unpredicted changes in nutrition or the patient’s health. If the glucose level rises above 180 mg/dL, IV insulin infusion should be started to maintain levels below 180 mg/dL.^13,26,28,29

A variety of infusion protocols have been shown to be effective in achieving glycemic control with a low rate of hypoglycemia. The ideal protocol should allow flexible rate adjustment taking into account current and previous glucose values as well as changes in infusion rate. Hourly glucose measurements until stable glycemic control is established, followed by point-of-care testing every 1 to 2 hours, is needed to assess response to therapy and prevent hypoglycemia.

Insulin regimens in noncritical care settings

For most patients in a general, non-ICU setting, SC insulin therapy with basal insulin administered once or twice daily, alone or in combination with prandial insulin, is effective and safe.¹³ Inhaled insulin is approved by the US Food and Drug Administration, but its use in the hospital has not been studied. The use of sliding-scale insulin is not acceptable as the single regimen in patients with diabetes, as it results in undesirable hypoglycemia and hyperglycemia.³⁰Figure 1 presents an algorithm for selecting initial insulin treatment for patients with type 2 diabetes in the non-ICU setting.

Basal insulin prevents hyperglycemia during fasting states. Basal insulin is usually given as a once- or twice-daily long-acting insulin, such as glargine and detemir insulin. On occasion, twice-daily intermediate-acting insulin (neutral protamine Hagedorn; NPH) is used as a basal insulin.

Prandial insulin, also referred to as nutritional or bolus insulin, is given before meals as rapid-acting insulin (aspart, lispro, or glulisine) or short-acting insulin (regular) to prevent postmeal hyperglycemia. Rapid-acting insulin is preferred to regular insulin because of the faster onset and shorter duration of action, which may reduce the risk of hypoglycemia.

Correction or supplemental insulin is given to correct hyperglycemia when the glucose is above the goal. The same formulation is given together with prandial insulin.

Total daily dose of insulin is a measure that comprises basal and prandial insulin Figure 1 lists the recommended total daily dose for different clinical situations and patient populations.

Basal-bolus insulin usually refers to a regimen of long-acting basal insulin plus prandial insulin. In patients with adequate oral intake, the basal-bolus approach is preferred. The RABBIT 2 trial reported that basal-bolus regimens resulted in greater improvement in glucose control than sliding-scale regimens (correction insulin alone without basal or prandial components) in general medicine patients with type 2 diabetes.³² In general surgery patients, basal-bolus regimens significantly improved glucose control and reduced the numbers of post­operative complications, primarily wound infections compared with sliding-scale regimens.⁴

Multiple doses of NPH and regular insulin were compared with basal-bolus treatment with long-acting and rapid-acting insulin in two controlled trials in medical patients with type 2 diabetes.^20,33 Both studies reported that treatment with NPH and regular insulin resulted in similar improvements in glycemic control and no difference in the rate of hypoglycemic events or in hospital length of stay, compared with basal-bolus insulin. Because NPH has a peak of action approximately 8 to 12 hours after injection, there is a risk of hypoglycemia in patients with poor oral intake.

In hospitalized patients who have reduced total caloric intake due to lack of appetite, acute illness, medical procedures, or surgical interventions, the Basal Plus trial³⁴ reported that a single daily dose of glargine plus correction doses of rapid-acting insulin resulted in similar improvement in glycemic control and no difference in the frequency of hypoglycemia compared with a standard basal-bolus regimen. These results indicate that the basal-plus-correction regimen may be preferred for patients with poor or no oral intake, whereas an insulin regimen with basal, nutritional (basal-bolus), and correction components is preferred for patients with good nutritional intake.³⁵

SC insulin dosing refers to insulin doses administered subcutaneously calculated based either on weight or on home insulin doses. For insulin-naive patients, the starting total daily dose of insulin can usually be computed as 0.4 to 0.5 U/kg/day. Higher starting doses are associated with greater odds of hypoglycemia than doses lower than 0.2 U/kg/day.³⁶ In elderly patients and those with impaired renal function, lower initial daily doses (≤ 0.3 U/kg) may reduce the risk of hypoglycemia.²⁶

In patients treated with insulin prior to admission, the total daily insulin dose at home can be given as half long-acting basal insulin and half prandial insulin. The dose can be reduced by 20% to 25% to prevent hypoglycemia, particularly in those with poor or uncertain caloric intake.³¹

Noninsulin therapies

The use of oral antidiabetic agents is generally not recommended in hospitalized patients due to the limited data available on their safety and efficacy, frequent contraindications, risk of hypoglycemia, and slow onset of action that may preclude achieving rapid glycemic control and daily dose adjustments. Table 3 lists the pros and cons of these agents in hospitalized patients.

The safety and efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the management of inpatient hyperglycemia was evaluated in a randomized pilot study in patients with type 2 diabetes treated at home with diet, oral antidiabetic agents, or a low daily insulin dose (≤ 0.4 U/kg/day).³⁷ Patients were randomized to one of two treatments:

• Sitagliptin alone or with low-dose glargine insulin
• Basal-bolus insulin regimen plus supplemental doses of insulin lispro.

Both treatment regimens resulted in similar improvement in mean daily glucose concentrations. However, patients admitted to the hospital with glucose levels above 180 mg/dL in the sitagliptin group had higher mean daily glucose levels than patients treated with basal-bolus or sitagliptin plus glargine.

Transitioning from IV to SC insulin

When patients in critical care units are ready to be transferred to a general medical floor, appropriate transition from IV insulin to scheduled SC insulin is needed to prevent rebound hyperglycemia. This is imperative in patients with type 1 diabetes in whom just a few hours without insulin can result in diabetic ketoacidosis.

There are three general ways to calculate the SC insulin dose during the transition period. The first two methods are weight-based and based on the home dose, as previously discussed. The third method is to extrapolate from the IV insulin. A common way is to sum up the total IV insulin dose in the past 6 or 8 hours and multiply by 3 or 4, and then reduce by 20% to achieve the basal insulin dose, presuming the patient had no oral intake on the IV insulin infusion. This last method is preferred in hemodynamically stable patients with stable insulin requirements.

If long-acting insulin is chosen as basal insulin, it should be given 2 to 4 hours before discontinuation of the IV insulin infusion. Intermediate-acting insulin should be given 1 to 2 hours before IV insulin discontinuation.

SPECIFIC SITUATIONS AND POPULATIONS

Type 1 diabetes

Patients with type 1 diabetes have minimal to absent pancreatic beta cell function and rely on the exogenous administration of insulin to maintain glucose homeostasis. They have worse glycemic control and higher rates of acute kidney injury than patients with type 2 diabetes; however, the impact of inpatient glycemic control on clinical outcomes has not been determined in patients with type 1 diabetes. Insulin therapy must provide both basal and nutritional components to achieve the target goals. It is important to ask the patient directly to determine the times and doses of prescribed insulin, medication adherence, recent dietary habits (including changes in appetite), and level of physical activity. This information will be used to guide insulin therapy.

A systematic review of 16 clinical studies reported that patients who possess excellent self-management skills can be suitable for successful inpatient diabetes self-management.³⁸ The American Diabetes Association supports patient self-management of diabetes in the hospital.³⁹ However, the competence and readiness of each patient with type 1 diabetes need to be carefully determined in an individualized manner. Potential candidates for inpatient self-management are those with unaltered mental status, proven proficient outpatient skills (eg, carbohydrate counting, frequent glucose monitoring, strong knowledge related to the management of insulin pump or injection techniques), and who are tolerating oral intake.

Enteral nutrition and tube feeding

Accidental dislodgement of feeding tubes, temporary discontinuation of nutrition due to nausea or for diagnostic testing, and cycling of enteral nutrition with oral intake in patients with an inconsistent appetite pose unique challenges in the hospital. Although it may be tempting to give basal and nutritional requirements to these patients as a single dose of long-acting insulin, this is not recommended. Low-dose basal insulin plus scheduled doses of short-acting (regular) insulin (every 6 hours) or rapid-acting insulin (every 4 hours) with correction insulin is often used. Some providers prefer giving intermediate-acting (NPH) plus short-acting (regular) insulin every 8 hours or every 12 hours.

It is generally accepted that diabetic enteral formulas that are low in carbohydrate and high in monounsaturated fatty acids are preferable to standard high-carbohydrate formulas in hospitalized patients with diabetes. In a meta-analysis, the postprandial rise in glucose was reduced by 20 to 30 mg/dL with the low-carbohydrate high-fat formulations compared with standard formulations.⁴⁰

Parenteral nutrition

The use of parenteral nutrition has been linked to aggravation of hyperglycemia independent of a history of diabetes as well as a higher risk of complications, infections, sepsis, and death.⁴¹ Regular insulin can be added to the parenteral solution at a starting dose of 0.1 U/g of dextrose in nondiabetic patients and at 0.15 U/g of dextrose in patients with diabetes.⁴²

Alternatively, insulin can be given as a continuous IV infusion. Hemodynamically stable patients with mild to moderate hyperglycemia can be managed with basal insulin plus scheduled or as-needed doses of short-acting (regular) insulin every 6 hours. To prevent waste, it is better to underestimate the insulin added to parenteral nutrition so as to avoid having to discontinue it prematurely or add additional glucose.

Glucocorticoids

Glucocorticoids typically raise glucose starting 4 to 6 hours after administration. Low doses of glucocorticoids given in the morning tend to raise the late morning to evening glucose levels without affecting the fasting glucose. In this situation, the patient may be managed on prandial insulin without long-acting basal insulin or with intermediate-acting insulin given in the morning. Higher glucocorticoid doses may raise fasting glucose levels, in which case basal-bolus insulin would be appropriate, with the basal component comprising about 30% and the bolus about 70% of the daily dose.²⁶

Insulin pump

Approximately 400,000 US patients with diabetes use an insulin pump.⁴³ Successful management of inpatient diabetes with the continuation of insulin pump therapy has been previously demonstrated in select patients. Clear hospital policies, procedures, and physicians’ orders with specifics on the type of diet, frequency of point-of-care glucose testing, and insulin doses (ie, basal rates, carbohydrate ratios, and correction formulas) should be in place. An inpatient diabetes specialist should assist with the assessment and management of a patient with an insulin pump.

If pump use is contraindicated (Table 4)⁴⁴ or if inpatient diabetes resources are not available, discontinuation of insulin pump and transition to a basal-bolus insulin regimen (“pump holiday”) may be the safest and most appropriate step. Most patients knowledgeable in insulin pump therapy are able to display in their pump screen the average total daily insulin used for the past few days. Based on this, safe estimations of basal, bolus, and supplemental insulin can be calculated. To avoid severe hyperglycemia or ketoacidosis from lack of basal insulin, it is important to administer the basal insulin component at least 2 hours before disconnecting the insulin pump.

Concentrated insulins

U-500 regular insulin is concentrated insulin that delivers the same amount of units in one-fifth the volume of conventional insulins, which are U-100. Whereas there are 100 units of insulin in 1 mL for conventional insulins, there are 500 units of U-500 regular insulin in 1 mL. Its onset of action is similar to that of regular insulin, and the peak and duration are similar to that of NPH insulin. Concentrated insulin is often administered in the outpatient setting to patients who are insulin resistant and require close to 200 units a day. The U-500 pen device was approved in January 2016 and was projected to be available in April 2016. For now, it can only be procured in the vial form. This causes confusion in its dosing since it is given either with the usual insulin syringes, which are designed for U-100 insulin administration, or a tuberculin syringe, which is not marked in units but in milliliters.

Because of its unique nature and providers’ lack of familiarity with U-500, certain institutions have a policy for its use. In many institutions, the doses are confirmed by pharmacy staff and delivered by pharmacy to the patient’s medication bin predrawn in a tuberculin syringe.⁴⁵ In addition, a study reported that many patients on U-500 at home required significantly lower doses of insulin (average dose of 100 U/day) while hospitalized patients could be managed with conventional insulin formulations.⁴⁵

There are newer concentrated insulins in the market, such as insulin glargine 300 U/mL (Toujeo) and insulin lispro 200 U/mL (Humalog). These insulins, so far, come only in the pen device form and not in vials, obviating the need for dose calculations using a U-100 insulin syringe or tuberculin syringe. The efficacy and safety of these insulin formulations have not been determined in the hospital setting.

Transitioning from home to hospital

Transition to an outpatient setting requires planning and coordination. Although insulin is used in the hospital for most patients with diabetes, many patients do not require insulin after discharge. On the other hand, diabetes regimens sometimes need intensification in other patients. One study showed that patients with acceptable diabetes control (HbA1c < 7.5%) near or on admission could be discharged on their prehospitalization treatment regimen, while those with HbA1c between 7.5% and 9% could be discharged on oral agents plus basal insulin at 50% of the hospital basal dose.⁴⁶ Additionally, patients with an HbA1c of 9% to 10% should be discharged on a basal-bolus regimen or on a combination of oral agents plus basal insulin at 80% of hospital dose, with a reduction in HbA1c seen 12 weeks after discharge.

SUMMARY

Inpatient hyperglycemia is common and is associated with increased risk of hospital complications, higher healthcare resource utilization, and higher rates of in-hospital mortality. In the critically ill, IV insulin is most appropriate, with a starting threshold no higher than 180 mg/dL. Once IV insulin is started, the glucose level should be maintained between 140 and 180 mg/dL.

In noncritically ill patients, a basal-bolus regimen with basal, prandial, and correction components is preferred for patients with good nutritional intake. In contrast, a single dose of long-acting insulin plus correction insulin is preferred for patients with poor or no oral intake. Preliminary data indicate that incretin therapy has the potential to improve glycemic control in patients with mild to moderate hyperglycemia and a low risk of hypoglycemia.

Transition to an outpatient setting requires planning and coordination. Measuring HbA1c at admission is important to assess preadmission glycemic control and to tailor the treatment regimen at discharge. Patients with acceptable diabetes control could be discharged on their prehospitalization treatment regimen. Patients with suboptimal control should have more intensified therapy.

Dr. Umpierrez is supported in part by research grants from the American Diabetes Association (1-14-LLY-36), PHS grant UL1 RR025008 from the Clinical Translational Science Award Program (M01 RR-00039), and grants from the National Institutes of Health and the National Center for Research Resources. He has received unrestricted research support for inpatient studies (at Emory University) from Sanofi, Merck, Novo Nordisk, and Boehringer Ingelheim, and has received consulting fees and/or honoraria for membership on advisory boards from Novo Nordisk, Sanofi, Merck, Boehringer Ingelheim, and Regeneron.
 

Hyperglycemia in hospitalized patients, with or without diabetes, is associated with adverse outcomes including increased rates of infection and mortality and longer hospital length of stay.^1–3 The rates of complications and mortality are even higher in hyperglycemic patients without a history of diabetes than in those with diabetes.^1,2 Randomized clinical trials in critically ill and noncritically ill hyperglycemic patients demonstrate that improved glycemic control can reduce hospital complications, systemic infections, and hospitalization cost.^4–6 However, intensive glycemic therapy is associated with increased risk of hypoglycemia, which is independently associated with increased morbidity and mortality in hospitalized patients. The concern about hypoglycemia has led to revised blood glucose target recommendations from professional organizations and a search for alternative treatment options.

This manuscript provides a review of updated recommendations for the management of inpatients with hyperglycemia in the critical care and general medical and surgical settings.

HYPERGLYCEMIA IN CRITICAL CARE SETTINGS

A substantial body of evidence links hyperglycemia in critically ill patients to higher rates of hospital complications, longer hospital stay, higher healthcare resource utilization, and greater hospital mortality.^7,8 Although evidence from several cohort studies and randomized clinical trials suggests that tight glucose control can reduce hospital complications and mortality,^9,10 this target has been difficult to achieve without increasing the risk of severe hypoglycemia. In addition, data from trials using intense glycemic control in patients in the intensive care unit (ICU) have failed to show a significant improvement in mortality and, in some instances, showed increased mortality risk associated with the therapy.^11,12

The recommended target glucose levels are 140 to 180 mg/dL for most ICU patients.¹³ In agreement with this, the recent GLUCO-CABG trial reported no significant differences in the composite end points of complications and death between an intensive glucose target of 100 to 140 mg/dL and a conservative target of 141 to 180 mg/dL after cardiac surgery.¹⁴

HYPERGLYCEMIA IN NONCRITICAL CARE SETTINGS

In general medical and surgical patients, a strong association has been reported between hyperglycemia and prolonged hospital stay, infection, and disability after hospital discharge.^1,15,16 For example, the risk of postoperative infections in patients undergoing general surgery was estimated to increase by 30% for every 40 mg/dL rise in glucose over normo­glycemia (< 110 mg/dL).¹⁶ In general, appropriate glycemic control to maintain recommended glycemic levels in noncritically ill patients can reduce the risks and improve outcomes. 

HYPOGLYCEMIA INCIDENCE

Hypoglycemia, defined as glucose less than 70 mg/dL, is a common complication of hyperglycemia treatment.¹⁷ Severe hypoglycemia is defined as glucose less than 40 mg/dL.¹⁸ The incidence of hypoglycemia in ICU trials ranged between 5% and 28%, depending on the intensity of glycemic control,¹⁹ and between 1% and 33% in non-ICU trials using subcutaneous (SC) insulin therapy.²⁰ The most important hypoglycemia risk factors include older age, kidney failure, change in nutritional intake, interruption of glucose monitoring, previous insulin therapy, and failure to adjust therapy when glucose is trending down or steroid therapy is being tapered.^21,22

In hospitalized patients with diabetes, hypoglycemia has been associated with poor outcomes, including a 66% increased risk of death within 1 year and 2.8 days longer hospital stay compared with patients without hypoglycemia.²³ Hypoglycemia also has been associated with prolonged QT interval, ischemic electro­cardiogram changes, angina, arrhythmias, and sudden death in patients with type 1 diabetes.²⁴ Despite these observations, other studies have reported that the increased in-hospital mortality rate is limited to patients with spontaneous hypoglycemia rather than drug-associated hypoglycemia,²⁵ raising the possibility that hypoglycemia may represent a marker of disease burden rather than be a direct cause of death.

INPATIENT ASSESSMENT OF HYPERGLYCEMIA

Clinical guidelines recommend glucose measurement in all patients admitted to the hospital.^13,26 Patients with hyperglycemia (glucose > 140 mg/dL) and patients with a history of diabetes should undergo bedside point-of-care glucose testing before meals and at bedtime. Premeal testing should be done close to the time of the meal tray delivery and no longer than 1 hour before meals. For patients taking nothing by mouth or receiving continuous enteral nutrition, point-of-care testing is recommended every 4 to 6 hours.

Hemoglobin A1c (HbA1c) should be measured in patients with hyperglycemia and in those with diabetes if it has not been performed in the preceding 2 to 3 months. In hyperglycemic patients without a history of diabetes, an HbA1c of 6.5% or greater suggests that diabetes preceded hospitalization. In patients with diabetes, the HbA1c can help assess glycemic control prior to admission and tailor the treatment regimen at discharge.^13,26

TARGET GLUCOSE LEVELS

Glycemic targets recommended by several organizations are shown in Table 1. For critically ill patients, most societies recommend glucose targets below 180 mg/dL, with the lower limit being anywhere from 110 to less than 150 mg/dL.

For patients in non-ICU settings, the Endocrine Society²⁶ and the American Diabetes Association/American Association of Endocrinologists¹³ practice guidelines recommend premeal glucose levels below 140 mg/dL, and below 180 mg/dL if checked randomly. Higher glucose ranges (< 200 mg/dL) may be acceptable in terminally ill patients or in patients with severe comorbidities.²⁶ Guidelines from the Joint British Diabetes Societies recommend targeting glucose levels between 108 and 180 mg/dL with an acceptable range of between 72 and 216 mg/dL.²⁷

INPATIENT MANAGEMENT OF HYPERGLYCEMIA AND DIABETES

Insulin regimens in critical care settings

Insulin administration is the preferred way to control hyperglycemia in hospitalized patients. In critically ill patients, such as those with hypotension requiring pressor support, hyperglycemic crises, sepsis, or shock, insulin is best given via continuous intravenous (IV) infusion. The short half-life of IV insulin (< 15 minutes) allows flexibility in adjusting the infusion rate in the event of unpredicted changes in nutrition or the patient’s health. If the glucose level rises above 180 mg/dL, IV insulin infusion should be started to maintain levels below 180 mg/dL.^13,26,28,29

A variety of infusion protocols have been shown to be effective in achieving glycemic control with a low rate of hypoglycemia. The ideal protocol should allow flexible rate adjustment taking into account current and previous glucose values as well as changes in infusion rate. Hourly glucose measurements until stable glycemic control is established, followed by point-of-care testing every 1 to 2 hours, is needed to assess response to therapy and prevent hypoglycemia.

Insulin regimens in noncritical care settings

For most patients in a general, non-ICU setting, SC insulin therapy with basal insulin administered once or twice daily, alone or in combination with prandial insulin, is effective and safe.¹³ Inhaled insulin is approved by the US Food and Drug Administration, but its use in the hospital has not been studied. The use of sliding-scale insulin is not acceptable as the single regimen in patients with diabetes, as it results in undesirable hypoglycemia and hyperglycemia.³⁰Figure 1 presents an algorithm for selecting initial insulin treatment for patients with type 2 diabetes in the non-ICU setting.

Basal insulin prevents hyperglycemia during fasting states. Basal insulin is usually given as a once- or twice-daily long-acting insulin, such as glargine and detemir insulin. On occasion, twice-daily intermediate-acting insulin (neutral protamine Hagedorn; NPH) is used as a basal insulin.

Prandial insulin, also referred to as nutritional or bolus insulin, is given before meals as rapid-acting insulin (aspart, lispro, or glulisine) or short-acting insulin (regular) to prevent postmeal hyperglycemia. Rapid-acting insulin is preferred to regular insulin because of the faster onset and shorter duration of action, which may reduce the risk of hypoglycemia.

Correction or supplemental insulin is given to correct hyperglycemia when the glucose is above the goal. The same formulation is given together with prandial insulin.

Total daily dose of insulin is a measure that comprises basal and prandial insulin Figure 1 lists the recommended total daily dose for different clinical situations and patient populations.

Basal-bolus insulin usually refers to a regimen of long-acting basal insulin plus prandial insulin. In patients with adequate oral intake, the basal-bolus approach is preferred. The RABBIT 2 trial reported that basal-bolus regimens resulted in greater improvement in glucose control than sliding-scale regimens (correction insulin alone without basal or prandial components) in general medicine patients with type 2 diabetes.³² In general surgery patients, basal-bolus regimens significantly improved glucose control and reduced the numbers of post­operative complications, primarily wound infections compared with sliding-scale regimens.⁴

Multiple doses of NPH and regular insulin were compared with basal-bolus treatment with long-acting and rapid-acting insulin in two controlled trials in medical patients with type 2 diabetes.^20,33 Both studies reported that treatment with NPH and regular insulin resulted in similar improvements in glycemic control and no difference in the rate of hypoglycemic events or in hospital length of stay, compared with basal-bolus insulin. Because NPH has a peak of action approximately 8 to 12 hours after injection, there is a risk of hypoglycemia in patients with poor oral intake.

In hospitalized patients who have reduced total caloric intake due to lack of appetite, acute illness, medical procedures, or surgical interventions, the Basal Plus trial³⁴ reported that a single daily dose of glargine plus correction doses of rapid-acting insulin resulted in similar improvement in glycemic control and no difference in the frequency of hypoglycemia compared with a standard basal-bolus regimen. These results indicate that the basal-plus-correction regimen may be preferred for patients with poor or no oral intake, whereas an insulin regimen with basal, nutritional (basal-bolus), and correction components is preferred for patients with good nutritional intake.³⁵

SC insulin dosing refers to insulin doses administered subcutaneously calculated based either on weight or on home insulin doses. For insulin-naive patients, the starting total daily dose of insulin can usually be computed as 0.4 to 0.5 U/kg/day. Higher starting doses are associated with greater odds of hypoglycemia than doses lower than 0.2 U/kg/day.³⁶ In elderly patients and those with impaired renal function, lower initial daily doses (≤ 0.3 U/kg) may reduce the risk of hypoglycemia.²⁶

In patients treated with insulin prior to admission, the total daily insulin dose at home can be given as half long-acting basal insulin and half prandial insulin. The dose can be reduced by 20% to 25% to prevent hypoglycemia, particularly in those with poor or uncertain caloric intake.³¹

Noninsulin therapies

The use of oral antidiabetic agents is generally not recommended in hospitalized patients due to the limited data available on their safety and efficacy, frequent contraindications, risk of hypoglycemia, and slow onset of action that may preclude achieving rapid glycemic control and daily dose adjustments. Table 3 lists the pros and cons of these agents in hospitalized patients.

The safety and efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the management of inpatient hyperglycemia was evaluated in a randomized pilot study in patients with type 2 diabetes treated at home with diet, oral antidiabetic agents, or a low daily insulin dose (≤ 0.4 U/kg/day).³⁷ Patients were randomized to one of two treatments:

• Sitagliptin alone or with low-dose glargine insulin
• Basal-bolus insulin regimen plus supplemental doses of insulin lispro.

Both treatment regimens resulted in similar improvement in mean daily glucose concentrations. However, patients admitted to the hospital with glucose levels above 180 mg/dL in the sitagliptin group had higher mean daily glucose levels than patients treated with basal-bolus or sitagliptin plus glargine.

Transitioning from IV to SC insulin

When patients in critical care units are ready to be transferred to a general medical floor, appropriate transition from IV insulin to scheduled SC insulin is needed to prevent rebound hyperglycemia. This is imperative in patients with type 1 diabetes in whom just a few hours without insulin can result in diabetic ketoacidosis.

There are three general ways to calculate the SC insulin dose during the transition period. The first two methods are weight-based and based on the home dose, as previously discussed. The third method is to extrapolate from the IV insulin. A common way is to sum up the total IV insulin dose in the past 6 or 8 hours and multiply by 3 or 4, and then reduce by 20% to achieve the basal insulin dose, presuming the patient had no oral intake on the IV insulin infusion. This last method is preferred in hemodynamically stable patients with stable insulin requirements.

If long-acting insulin is chosen as basal insulin, it should be given 2 to 4 hours before discontinuation of the IV insulin infusion. Intermediate-acting insulin should be given 1 to 2 hours before IV insulin discontinuation.

SPECIFIC SITUATIONS AND POPULATIONS

Type 1 diabetes

Patients with type 1 diabetes have minimal to absent pancreatic beta cell function and rely on the exogenous administration of insulin to maintain glucose homeostasis. They have worse glycemic control and higher rates of acute kidney injury than patients with type 2 diabetes; however, the impact of inpatient glycemic control on clinical outcomes has not been determined in patients with type 1 diabetes. Insulin therapy must provide both basal and nutritional components to achieve the target goals. It is important to ask the patient directly to determine the times and doses of prescribed insulin, medication adherence, recent dietary habits (including changes in appetite), and level of physical activity. This information will be used to guide insulin therapy.

A systematic review of 16 clinical studies reported that patients who possess excellent self-management skills can be suitable for successful inpatient diabetes self-management.³⁸ The American Diabetes Association supports patient self-management of diabetes in the hospital.³⁹ However, the competence and readiness of each patient with type 1 diabetes need to be carefully determined in an individualized manner. Potential candidates for inpatient self-management are those with unaltered mental status, proven proficient outpatient skills (eg, carbohydrate counting, frequent glucose monitoring, strong knowledge related to the management of insulin pump or injection techniques), and who are tolerating oral intake.

Enteral nutrition and tube feeding

Accidental dislodgement of feeding tubes, temporary discontinuation of nutrition due to nausea or for diagnostic testing, and cycling of enteral nutrition with oral intake in patients with an inconsistent appetite pose unique challenges in the hospital. Although it may be tempting to give basal and nutritional requirements to these patients as a single dose of long-acting insulin, this is not recommended. Low-dose basal insulin plus scheduled doses of short-acting (regular) insulin (every 6 hours) or rapid-acting insulin (every 4 hours) with correction insulin is often used. Some providers prefer giving intermediate-acting (NPH) plus short-acting (regular) insulin every 8 hours or every 12 hours.

It is generally accepted that diabetic enteral formulas that are low in carbohydrate and high in monounsaturated fatty acids are preferable to standard high-carbohydrate formulas in hospitalized patients with diabetes. In a meta-analysis, the postprandial rise in glucose was reduced by 20 to 30 mg/dL with the low-carbohydrate high-fat formulations compared with standard formulations.⁴⁰

Parenteral nutrition

The use of parenteral nutrition has been linked to aggravation of hyperglycemia independent of a history of diabetes as well as a higher risk of complications, infections, sepsis, and death.⁴¹ Regular insulin can be added to the parenteral solution at a starting dose of 0.1 U/g of dextrose in nondiabetic patients and at 0.15 U/g of dextrose in patients with diabetes.⁴²

Alternatively, insulin can be given as a continuous IV infusion. Hemodynamically stable patients with mild to moderate hyperglycemia can be managed with basal insulin plus scheduled or as-needed doses of short-acting (regular) insulin every 6 hours. To prevent waste, it is better to underestimate the insulin added to parenteral nutrition so as to avoid having to discontinue it prematurely or add additional glucose.

Glucocorticoids

Glucocorticoids typically raise glucose starting 4 to 6 hours after administration. Low doses of glucocorticoids given in the morning tend to raise the late morning to evening glucose levels without affecting the fasting glucose. In this situation, the patient may be managed on prandial insulin without long-acting basal insulin or with intermediate-acting insulin given in the morning. Higher glucocorticoid doses may raise fasting glucose levels, in which case basal-bolus insulin would be appropriate, with the basal component comprising about 30% and the bolus about 70% of the daily dose.²⁶

Insulin pump

Approximately 400,000 US patients with diabetes use an insulin pump.⁴³ Successful management of inpatient diabetes with the continuation of insulin pump therapy has been previously demonstrated in select patients. Clear hospital policies, procedures, and physicians’ orders with specifics on the type of diet, frequency of point-of-care glucose testing, and insulin doses (ie, basal rates, carbohydrate ratios, and correction formulas) should be in place. An inpatient diabetes specialist should assist with the assessment and management of a patient with an insulin pump.

If pump use is contraindicated (Table 4)⁴⁴ or if inpatient diabetes resources are not available, discontinuation of insulin pump and transition to a basal-bolus insulin regimen (“pump holiday”) may be the safest and most appropriate step. Most patients knowledgeable in insulin pump therapy are able to display in their pump screen the average total daily insulin used for the past few days. Based on this, safe estimations of basal, bolus, and supplemental insulin can be calculated. To avoid severe hyperglycemia or ketoacidosis from lack of basal insulin, it is important to administer the basal insulin component at least 2 hours before disconnecting the insulin pump.

Concentrated insulins

U-500 regular insulin is concentrated insulin that delivers the same amount of units in one-fifth the volume of conventional insulins, which are U-100. Whereas there are 100 units of insulin in 1 mL for conventional insulins, there are 500 units of U-500 regular insulin in 1 mL. Its onset of action is similar to that of regular insulin, and the peak and duration are similar to that of NPH insulin. Concentrated insulin is often administered in the outpatient setting to patients who are insulin resistant and require close to 200 units a day. The U-500 pen device was approved in January 2016 and was projected to be available in April 2016. For now, it can only be procured in the vial form. This causes confusion in its dosing since it is given either with the usual insulin syringes, which are designed for U-100 insulin administration, or a tuberculin syringe, which is not marked in units but in milliliters.

Because of its unique nature and providers’ lack of familiarity with U-500, certain institutions have a policy for its use. In many institutions, the doses are confirmed by pharmacy staff and delivered by pharmacy to the patient’s medication bin predrawn in a tuberculin syringe.⁴⁵ In addition, a study reported that many patients on U-500 at home required significantly lower doses of insulin (average dose of 100 U/day) while hospitalized patients could be managed with conventional insulin formulations.⁴⁵

There are newer concentrated insulins in the market, such as insulin glargine 300 U/mL (Toujeo) and insulin lispro 200 U/mL (Humalog). These insulins, so far, come only in the pen device form and not in vials, obviating the need for dose calculations using a U-100 insulin syringe or tuberculin syringe. The efficacy and safety of these insulin formulations have not been determined in the hospital setting.

Transitioning from home to hospital

Transition to an outpatient setting requires planning and coordination. Although insulin is used in the hospital for most patients with diabetes, many patients do not require insulin after discharge. On the other hand, diabetes regimens sometimes need intensification in other patients. One study showed that patients with acceptable diabetes control (HbA1c < 7.5%) near or on admission could be discharged on their prehospitalization treatment regimen, while those with HbA1c between 7.5% and 9% could be discharged on oral agents plus basal insulin at 50% of the hospital basal dose.⁴⁶ Additionally, patients with an HbA1c of 9% to 10% should be discharged on a basal-bolus regimen or on a combination of oral agents plus basal insulin at 80% of hospital dose, with a reduction in HbA1c seen 12 weeks after discharge.

SUMMARY

Inpatient hyperglycemia is common and is associated with increased risk of hospital complications, higher healthcare resource utilization, and higher rates of in-hospital mortality. In the critically ill, IV insulin is most appropriate, with a starting threshold no higher than 180 mg/dL. Once IV insulin is started, the glucose level should be maintained between 140 and 180 mg/dL.

In noncritically ill patients, a basal-bolus regimen with basal, prandial, and correction components is preferred for patients with good nutritional intake. In contrast, a single dose of long-acting insulin plus correction insulin is preferred for patients with poor or no oral intake. Preliminary data indicate that incretin therapy has the potential to improve glycemic control in patients with mild to moderate hyperglycemia and a low risk of hypoglycemia.

Transition to an outpatient setting requires planning and coordination. Measuring HbA1c at admission is important to assess preadmission glycemic control and to tailor the treatment regimen at discharge. Patients with acceptable diabetes control could be discharged on their prehospitalization treatment regimen. Patients with suboptimal control should have more intensified therapy.

Dr. Umpierrez is supported in part by research grants from the American Diabetes Association (1-14-LLY-36), PHS grant UL1 RR025008 from the Clinical Translational Science Award Program (M01 RR-00039), and grants from the National Institutes of Health and the National Center for Research Resources. He has received unrestricted research support for inpatient studies (at Emory University) from Sanofi, Merck, Novo Nordisk, and Boehringer Ingelheim, and has received consulting fees and/or honoraria for membership on advisory boards from Novo Nordisk, Sanofi, Merck, Boehringer Ingelheim, and Regeneron.
 

People who live in areas with more intense outdoor nighttime light radiance are more likely to go to bed after midnight, get fewer than 6 hours of sleep, and be dissatisfied with their sleep, compared with people who live in areas with less intense nighttime light radiance, according to research presented at the 68th Annual Meeting of the American Academy of Neurology. The researchers noted that if this association between outdoor nighttime light exposure and changes in sleep habits is confirmed by other studies, people may want to consider room darkening shades, sleep masks, or other options to reduce their exposure to nighttime light. An overview of the research is available at Neurology Reviews: http://www.neurologyreviews.com/the-publication/issue-single-view/nighttime-light-radiance-affects-sleep/d1f539419c140f8f9c536881cdb1d3d5.html.

People who live in areas with more intense outdoor nighttime light radiance are more likely to go to bed after midnight, get fewer than 6 hours of sleep, and be dissatisfied with their sleep, compared with people who live in areas with less intense nighttime light radiance, according to research presented at the 68th Annual Meeting of the American Academy of Neurology. The researchers noted that if this association between outdoor nighttime light exposure and changes in sleep habits is confirmed by other studies, people may want to consider room darkening shades, sleep masks, or other options to reduce their exposure to nighttime light. An overview of the research is available at Neurology Reviews: http://www.neurologyreviews.com/the-publication/issue-single-view/nighttime-light-radiance-affects-sleep/d1f539419c140f8f9c536881cdb1d3d5.html.

People who live in areas with more intense outdoor nighttime light radiance are more likely to go to bed after midnight, get fewer than 6 hours of sleep, and be dissatisfied with their sleep, compared with people who live in areas with less intense nighttime light radiance, according to research presented at the 68th Annual Meeting of the American Academy of Neurology. The researchers noted that if this association between outdoor nighttime light exposure and changes in sleep habits is confirmed by other studies, people may want to consider room darkening shades, sleep masks, or other options to reduce their exposure to nighttime light. An overview of the research is available at Neurology Reviews: http://www.neurologyreviews.com/the-publication/issue-single-view/nighttime-light-radiance-affects-sleep/d1f539419c140f8f9c536881cdb1d3d5.html.

In this case report, the authors describe their experience in caring for a 62-year-old man with hepatic decompensation and acute kidney injury that was caused by simeprevir/sofosbuvir initiation for chronic hepatitis C (HCV). In the article, which is available at http://www.fedprac.com/the-publication/issue-single-view/possible-simeprevirsofosbuvir-induced-hepatic-decompensation-with-acute-kidney-failure/4aa123f84bba6831d73a86fd67565a5e/ocregister.html, the authors advise that careful consideration is needed prior to the initiation of simeprevir/sofosbuvir—particularly in patients with advanced liver disease or known hepatocellular carcinoma and baseline renal impairment.

In this case report, the authors describe their experience in caring for a 62-year-old man with hepatic decompensation and acute kidney injury that was caused by simeprevir/sofosbuvir initiation for chronic hepatitis C (HCV). In the article, which is available at http://www.fedprac.com/the-publication/issue-single-view/possible-simeprevirsofosbuvir-induced-hepatic-decompensation-with-acute-kidney-failure/4aa123f84bba6831d73a86fd67565a5e/ocregister.html, the authors advise that careful consideration is needed prior to the initiation of simeprevir/sofosbuvir—particularly in patients with advanced liver disease or known hepatocellular carcinoma and baseline renal impairment.

In this case report, the authors describe their experience in caring for a 62-year-old man with hepatic decompensation and acute kidney injury that was caused by simeprevir/sofosbuvir initiation for chronic hepatitis C (HCV). In the article, which is available at http://www.fedprac.com/the-publication/issue-single-view/possible-simeprevirsofosbuvir-induced-hepatic-decompensation-with-acute-kidney-failure/4aa123f84bba6831d73a86fd67565a5e/ocregister.html, the authors advise that careful consideration is needed prior to the initiation of simeprevir/sofosbuvir—particularly in patients with advanced liver disease or known hepatocellular carcinoma and baseline renal impairment.

High-dose oral vitamin D supplements taken for one year significantly improved cardiac structure and function in patients with chronic heart failure (CHF) secondary to left ventricular systolic dysfunction, according to results from a new study published online in the Journal of the American College of Cardiology. However, the study, led by Dr. Klaus Witte of the University of Leeds (England), found that 6-minute walk-distance—the study’s primary outcome measure—was not improved after a year’s supplementation with vitamin D. For more on the study, go to Cardiology News: http://www.ecardiologynews.com/specialty-focus/heart-failure/single-article-page/high-dose-vitamin-d-improves-heart-structure-function-in-chronic-heart-failure/ddee3f3aef17d20293b99a606045ef98.html.

High-dose oral vitamin D supplements taken for one year significantly improved cardiac structure and function in patients with chronic heart failure (CHF) secondary to left ventricular systolic dysfunction, according to results from a new study published online in the Journal of the American College of Cardiology. However, the study, led by Dr. Klaus Witte of the University of Leeds (England), found that 6-minute walk-distance—the study’s primary outcome measure—was not improved after a year’s supplementation with vitamin D. For more on the study, go to Cardiology News: http://www.ecardiologynews.com/specialty-focus/heart-failure/single-article-page/high-dose-vitamin-d-improves-heart-structure-function-in-chronic-heart-failure/ddee3f3aef17d20293b99a606045ef98.html.

High-dose oral vitamin D supplements taken for one year significantly improved cardiac structure and function in patients with chronic heart failure (CHF) secondary to left ventricular systolic dysfunction, according to results from a new study published online in the Journal of the American College of Cardiology. However, the study, led by Dr. Klaus Witte of the University of Leeds (England), found that 6-minute walk-distance—the study’s primary outcome measure—was not improved after a year’s supplementation with vitamin D. For more on the study, go to Cardiology News: http://www.ecardiologynews.com/specialty-focus/heart-failure/single-article-page/high-dose-vitamin-d-improves-heart-structure-function-in-chronic-heart-failure/ddee3f3aef17d20293b99a606045ef98.html.

Pioglitazone, which is used to treat type 2 diabetes, may reduce the risk of recurrent stroke and heart attacks by 24% in people who are insulin resistant but do not have diabetes, according to findings from the Insulin Resistance Intervention after Stroke (IRIS) trial. The study, supported by the National Institute of Neurological Disorders and Stroke, is the first to provide evidence that suggests a drug that targets cell metabolism may be protective against recurrent vascular events even before diabetes develops. More information on the study is available at Federal Practitioner: http://www.fedprac.com/the-publication/issue-single-view/diabetes-drug-reduces-recurrent-vascular-events/bd40f959f882ada3b88cfaa670c4fa44/ocregister.html.

Pioglitazone, which is used to treat type 2 diabetes, may reduce the risk of recurrent stroke and heart attacks by 24% in people who are insulin resistant but do not have diabetes, according to findings from the Insulin Resistance Intervention after Stroke (IRIS) trial. The study, supported by the National Institute of Neurological Disorders and Stroke, is the first to provide evidence that suggests a drug that targets cell metabolism may be protective against recurrent vascular events even before diabetes develops. More information on the study is available at Federal Practitioner: http://www.fedprac.com/the-publication/issue-single-view/diabetes-drug-reduces-recurrent-vascular-events/bd40f959f882ada3b88cfaa670c4fa44/ocregister.html.

Pioglitazone, which is used to treat type 2 diabetes, may reduce the risk of recurrent stroke and heart attacks by 24% in people who are insulin resistant but do not have diabetes, according to findings from the Insulin Resistance Intervention after Stroke (IRIS) trial. The study, supported by the National Institute of Neurological Disorders and Stroke, is the first to provide evidence that suggests a drug that targets cell metabolism may be protective against recurrent vascular events even before diabetes develops. More information on the study is available at Federal Practitioner: http://www.fedprac.com/the-publication/issue-single-view/diabetes-drug-reduces-recurrent-vascular-events/bd40f959f882ada3b88cfaa670c4fa44/ocregister.html.

What does your patient need to know at the first visit? Does it apply to patients of all genders and ages?

Before performing laser procedures on patients with richly pigmented skin (Fitzpatrick skin types IV–VI), patients need to be informed of the higher risk for pigmentary alterations as potential complications of the procedure. Specifically, hyperpigmentation or hypopigmentation can occur postprocedure, depending on the type of device used, the treatment settings, the technique, the underlying skin disorder being treated, and the patient’s individual response to treatment. Fortunately, these pigment alterations are in most cases self-limited but can last for weeks to months depending on the severity and the nature of the dyspigmentation.

What are your go-to treatments? What are the side effects?

Notwithstanding the higher risks for pigmentary alterations, lasers can be extremely useful for the management of numerous dermatologic concerns in patients with Fitzpatrick skin types IV to VI including laser hair removal for pseudofolliculitis barbae or nonablative fractional laser resurfacing for acne scarring and pigmentary disorders. My go-to treatments include the following: long-pulsed 1064-nm Nd:YAG laser for hair removal in Fitzpatrick skin types V to VI, 808-nm diode laser with linear scanning of hair removal in Fitzpatrick skin type IV or less, 1550-nm erbium-doped nonablative fractional laser for acne scarring in Fitzpatrick skin types IV to VI, and low-power diode 1927-nm fractional laser for melasma and postinflammatory hyperpigmentation in Fitzpatrick skin types IV to VI.

All of these procedures are performed with conservative treatment settings such as low fluences and longer pulse durations for laser hair removal and low treatment densities for fractional laser procedures. Prior to laser resurfacing, I recommend hydroquinone cream 4% twice daily starting 2 weeks before the first session and for 4 weeks posttreatment. These recommendations are based on published evidence (see Suggested Readings) as well as anecdotal experience.

How do you keep patients compliant with treatment?

Emphasizing the need for broad-spectrum sunscreen and avoidance of intense sun exposure before and after laser treatments is important during the initial consultation and prior to each treatment. I warn my patients of the higher risk for hyperpigmentation if the skin is tanned or has recently had intense sun exposure.

What do you do if they refuse treatment?

If patients refuse laser treatment or recommended precautions, then I will consider nonlaser treatment options.

What resources do you recommend to patients for more information?

I recommend patients visit the Skin of Color Society website (www.skinofcolorsociety.org).

Suggested Readings

• Alexis AF. Fractional laser resurfacing of acne scarring in patients with Fitzpatrick skin types IV-VI. J Drugs Dermatol. 2011;10(12 suppl):s6-s7.
• Alexis AF. Lasers and light-based therapies in ethnic skin: treatment options and recommendations for Fitzpatrick skin types V and VI. Br J Dermatol. 2013;169(suppl 3):91-97.
• Alexis AF, Coley MK, Nijhawan RI, et al. Nonablative fractional laser resurfacing for acne scarring in patients with Fitzpatrick skin phototypes IV-VI. Dermatol Surg. 2016;42:392-402.
• Battle EF, Hobbs LM. Laser-assisted hair removal for darker skin types. Dermatol Ther. 2004;17:177-183.
• Clark CM, Silverberg JI, Alexis AF. A retrospective chart review to assess the safety of nonablative fractional laser resurfacing in Fitzpatrick skin types IV to VI. J Drugs Dermatol. 2013;12:428-431.
• Ross EV, Cooke LM, Timko AL, et al. Treatment of pseudofolliculitis barbae in skin types IV, V, and VI with a long-pulsed neodymium:yttrium aluminum garnet laser. J Am Acad Dermatol. 2002;47:263-270.

What does your patient need to know at the first visit? Does it apply to patients of all genders and ages?

Before performing laser procedures on patients with richly pigmented skin (Fitzpatrick skin types IV–VI), patients need to be informed of the higher risk for pigmentary alterations as potential complications of the procedure. Specifically, hyperpigmentation or hypopigmentation can occur postprocedure, depending on the type of device used, the treatment settings, the technique, the underlying skin disorder being treated, and the patient’s individual response to treatment. Fortunately, these pigment alterations are in most cases self-limited but can last for weeks to months depending on the severity and the nature of the dyspigmentation.

What are your go-to treatments? What are the side effects?

Notwithstanding the higher risks for pigmentary alterations, lasers can be extremely useful for the management of numerous dermatologic concerns in patients with Fitzpatrick skin types IV to VI including laser hair removal for pseudofolliculitis barbae or nonablative fractional laser resurfacing for acne scarring and pigmentary disorders. My go-to treatments include the following: long-pulsed 1064-nm Nd:YAG laser for hair removal in Fitzpatrick skin types V to VI, 808-nm diode laser with linear scanning of hair removal in Fitzpatrick skin type IV or less, 1550-nm erbium-doped nonablative fractional laser for acne scarring in Fitzpatrick skin types IV to VI, and low-power diode 1927-nm fractional laser for melasma and postinflammatory hyperpigmentation in Fitzpatrick skin types IV to VI.

All of these procedures are performed with conservative treatment settings such as low fluences and longer pulse durations for laser hair removal and low treatment densities for fractional laser procedures. Prior to laser resurfacing, I recommend hydroquinone cream 4% twice daily starting 2 weeks before the first session and for 4 weeks posttreatment. These recommendations are based on published evidence (see Suggested Readings) as well as anecdotal experience.

How do you keep patients compliant with treatment?

Emphasizing the need for broad-spectrum sunscreen and avoidance of intense sun exposure before and after laser treatments is important during the initial consultation and prior to each treatment. I warn my patients of the higher risk for hyperpigmentation if the skin is tanned or has recently had intense sun exposure.

What do you do if they refuse treatment?

If patients refuse laser treatment or recommended precautions, then I will consider nonlaser treatment options.

What resources do you recommend to patients for more information?

I recommend patients visit the Skin of Color Society website (www.skinofcolorsociety.org).

Suggested Readings

• Alexis AF. Fractional laser resurfacing of acne scarring in patients with Fitzpatrick skin types IV-VI. J Drugs Dermatol. 2011;10(12 suppl):s6-s7.
• Alexis AF. Lasers and light-based therapies in ethnic skin: treatment options and recommendations for Fitzpatrick skin types V and VI. Br J Dermatol. 2013;169(suppl 3):91-97.
• Alexis AF, Coley MK, Nijhawan RI, et al. Nonablative fractional laser resurfacing for acne scarring in patients with Fitzpatrick skin phototypes IV-VI. Dermatol Surg. 2016;42:392-402.
• Battle EF, Hobbs LM. Laser-assisted hair removal for darker skin types. Dermatol Ther. 2004;17:177-183.
• Clark CM, Silverberg JI, Alexis AF. A retrospective chart review to assess the safety of nonablative fractional laser resurfacing in Fitzpatrick skin types IV to VI. J Drugs Dermatol. 2013;12:428-431.
• Ross EV, Cooke LM, Timko AL, et al. Treatment of pseudofolliculitis barbae in skin types IV, V, and VI with a long-pulsed neodymium:yttrium aluminum garnet laser. J Am Acad Dermatol. 2002;47:263-270.

What does your patient need to know at the first visit? Does it apply to patients of all genders and ages?

Before performing laser procedures on patients with richly pigmented skin (Fitzpatrick skin types IV–VI), patients need to be informed of the higher risk for pigmentary alterations as potential complications of the procedure. Specifically, hyperpigmentation or hypopigmentation can occur postprocedure, depending on the type of device used, the treatment settings, the technique, the underlying skin disorder being treated, and the patient’s individual response to treatment. Fortunately, these pigment alterations are in most cases self-limited but can last for weeks to months depending on the severity and the nature of the dyspigmentation.

What are your go-to treatments? What are the side effects?

Notwithstanding the higher risks for pigmentary alterations, lasers can be extremely useful for the management of numerous dermatologic concerns in patients with Fitzpatrick skin types IV to VI including laser hair removal for pseudofolliculitis barbae or nonablative fractional laser resurfacing for acne scarring and pigmentary disorders. My go-to treatments include the following: long-pulsed 1064-nm Nd:YAG laser for hair removal in Fitzpatrick skin types V to VI, 808-nm diode laser with linear scanning of hair removal in Fitzpatrick skin type IV or less, 1550-nm erbium-doped nonablative fractional laser for acne scarring in Fitzpatrick skin types IV to VI, and low-power diode 1927-nm fractional laser for melasma and postinflammatory hyperpigmentation in Fitzpatrick skin types IV to VI.

All of these procedures are performed with conservative treatment settings such as low fluences and longer pulse durations for laser hair removal and low treatment densities for fractional laser procedures. Prior to laser resurfacing, I recommend hydroquinone cream 4% twice daily starting 2 weeks before the first session and for 4 weeks posttreatment. These recommendations are based on published evidence (see Suggested Readings) as well as anecdotal experience.

How do you keep patients compliant with treatment?

Emphasizing the need for broad-spectrum sunscreen and avoidance of intense sun exposure before and after laser treatments is important during the initial consultation and prior to each treatment. I warn my patients of the higher risk for hyperpigmentation if the skin is tanned or has recently had intense sun exposure.

What do you do if they refuse treatment?

If patients refuse laser treatment or recommended precautions, then I will consider nonlaser treatment options.

What resources do you recommend to patients for more information?

I recommend patients visit the Skin of Color Society website (www.skinofcolorsociety.org).

Suggested Readings

• Alexis AF. Fractional laser resurfacing of acne scarring in patients with Fitzpatrick skin types IV-VI. J Drugs Dermatol. 2011;10(12 suppl):s6-s7.
• Alexis AF. Lasers and light-based therapies in ethnic skin: treatment options and recommendations for Fitzpatrick skin types V and VI. Br J Dermatol. 2013;169(suppl 3):91-97.
• Alexis AF, Coley MK, Nijhawan RI, et al. Nonablative fractional laser resurfacing for acne scarring in patients with Fitzpatrick skin phototypes IV-VI. Dermatol Surg. 2016;42:392-402.
• Battle EF, Hobbs LM. Laser-assisted hair removal for darker skin types. Dermatol Ther. 2004;17:177-183.
• Clark CM, Silverberg JI, Alexis AF. A retrospective chart review to assess the safety of nonablative fractional laser resurfacing in Fitzpatrick skin types IV to VI. J Drugs Dermatol. 2013;12:428-431.
• Ross EV, Cooke LM, Timko AL, et al. Treatment of pseudofolliculitis barbae in skin types IV, V, and VI with a long-pulsed neodymium:yttrium aluminum garnet laser. J Am Acad Dermatol. 2002;47:263-270.

CHICAGO – The abnormal arterial hemodynamics identified in 11-year-olds with an extremely preterm birth persist at age 19, according to an update from the landmark longitudinal EPICure study.

“Given the implications of these significant findings, cardiovascular monitoring and risk prevention would be highly recommended for all individuals born extremely preterm,” Dr. Joanne Beckmann said in presenting the EPICure results on the long-term consequences of extreme prematurity at the annual meeting of the American College of Cardiology.

EPICure is a longitudinal study investigating health outcomes in a national cohort of babies born extremely preterm at 22-25 weeks’ gestation in the United Kingdom during 1995-1996. It is the longest such study conducted anywhere.

“Neonatal survival at the lowest gestations has improved significantly since the 1990s with the advancement in neonatal care treatments and the implementation of evidence-based practices. Therefore, long-term health outcomes following extremely preterm birth will have increasing relevance to adult physicians,” observed Dr. Beckmann of University College London.

She reported on the results of detailed cardiovascular assessments conducted in 130 extremely premature EPICure participants and 64 matched controls who made it to London for 2 days of health testing when they turned 19 years of age. The findings update the results of similar comprehensive examinations done at age 11 years.

The extremely premature birth (EP) subjects were shorter and weighed less than did the controls. The two groups had similar seated systolic and diastolic blood pressure, and cardiac index didn’t differ between the two groups. However, the EP group had significantly higher supine central systolic and diastolic blood pressure and a higher heart rate.

Moreover, the increases in aortic augmentation index – a composite of arterial stiffness and global wave reflections – and total peripheral resistance seen in the EP group at age 11 years persisted at the 19-year mark. It’s unclear whether the abnormal peripheral resistance in the EP group is structural or functional in nature. All hemodynamic differences between the two groups remained significant after adjustment for potential confounders.

Aortic pulse wave velocity was not significantly different between the two groups of 19-year-olds.

Data pertaining to other aspects of health in the 19-year-olds are now being analyzed. At the age-11 assessment, the EP group was found to have significantly impaired lung function (J Pediatr. 2012 Oct;161[4]:595-601.e2), high risk for neurodevelopmental disability (Pediatrics. 2009 Aug;124[2]:3249-57), a high rate of learning impairments, and an 18-fold increased risk of poor academic attainment compared to their matched peers (Arch Dis Child Fetal Neonatal Ed. 2009 Jul;94[4]:F283-9).

EPICure is funded by the Medical Research Council. Dr. Beckmann reported having no financial conflicts of interest.

[email protected]

CHICAGO – The abnormal arterial hemodynamics identified in 11-year-olds with an extremely preterm birth persist at age 19, according to an update from the landmark longitudinal EPICure study.

“Given the implications of these significant findings, cardiovascular monitoring and risk prevention would be highly recommended for all individuals born extremely preterm,” Dr. Joanne Beckmann said in presenting the EPICure results on the long-term consequences of extreme prematurity at the annual meeting of the American College of Cardiology.

EPICure is a longitudinal study investigating health outcomes in a national cohort of babies born extremely preterm at 22-25 weeks’ gestation in the United Kingdom during 1995-1996. It is the longest such study conducted anywhere.

“Neonatal survival at the lowest gestations has improved significantly since the 1990s with the advancement in neonatal care treatments and the implementation of evidence-based practices. Therefore, long-term health outcomes following extremely preterm birth will have increasing relevance to adult physicians,” observed Dr. Beckmann of University College London.

She reported on the results of detailed cardiovascular assessments conducted in 130 extremely premature EPICure participants and 64 matched controls who made it to London for 2 days of health testing when they turned 19 years of age. The findings update the results of similar comprehensive examinations done at age 11 years.

The extremely premature birth (EP) subjects were shorter and weighed less than did the controls. The two groups had similar seated systolic and diastolic blood pressure, and cardiac index didn’t differ between the two groups. However, the EP group had significantly higher supine central systolic and diastolic blood pressure and a higher heart rate.

Moreover, the increases in aortic augmentation index – a composite of arterial stiffness and global wave reflections – and total peripheral resistance seen in the EP group at age 11 years persisted at the 19-year mark. It’s unclear whether the abnormal peripheral resistance in the EP group is structural or functional in nature. All hemodynamic differences between the two groups remained significant after adjustment for potential confounders.

Aortic pulse wave velocity was not significantly different between the two groups of 19-year-olds.

Data pertaining to other aspects of health in the 19-year-olds are now being analyzed. At the age-11 assessment, the EP group was found to have significantly impaired lung function (J Pediatr. 2012 Oct;161[4]:595-601.e2), high risk for neurodevelopmental disability (Pediatrics. 2009 Aug;124[2]:3249-57), a high rate of learning impairments, and an 18-fold increased risk of poor academic attainment compared to their matched peers (Arch Dis Child Fetal Neonatal Ed. 2009 Jul;94[4]:F283-9).

EPICure is funded by the Medical Research Council. Dr. Beckmann reported having no financial conflicts of interest.

[email protected]

CHICAGO – The abnormal arterial hemodynamics identified in 11-year-olds with an extremely preterm birth persist at age 19, according to an update from the landmark longitudinal EPICure study.

“Given the implications of these significant findings, cardiovascular monitoring and risk prevention would be highly recommended for all individuals born extremely preterm,” Dr. Joanne Beckmann said in presenting the EPICure results on the long-term consequences of extreme prematurity at the annual meeting of the American College of Cardiology.

EPICure is a longitudinal study investigating health outcomes in a national cohort of babies born extremely preterm at 22-25 weeks’ gestation in the United Kingdom during 1995-1996. It is the longest such study conducted anywhere.

“Neonatal survival at the lowest gestations has improved significantly since the 1990s with the advancement in neonatal care treatments and the implementation of evidence-based practices. Therefore, long-term health outcomes following extremely preterm birth will have increasing relevance to adult physicians,” observed Dr. Beckmann of University College London.

She reported on the results of detailed cardiovascular assessments conducted in 130 extremely premature EPICure participants and 64 matched controls who made it to London for 2 days of health testing when they turned 19 years of age. The findings update the results of similar comprehensive examinations done at age 11 years.

The extremely premature birth (EP) subjects were shorter and weighed less than did the controls. The two groups had similar seated systolic and diastolic blood pressure, and cardiac index didn’t differ between the two groups. However, the EP group had significantly higher supine central systolic and diastolic blood pressure and a higher heart rate.

Moreover, the increases in aortic augmentation index – a composite of arterial stiffness and global wave reflections – and total peripheral resistance seen in the EP group at age 11 years persisted at the 19-year mark. It’s unclear whether the abnormal peripheral resistance in the EP group is structural or functional in nature. All hemodynamic differences between the two groups remained significant after adjustment for potential confounders.

Aortic pulse wave velocity was not significantly different between the two groups of 19-year-olds.

Data pertaining to other aspects of health in the 19-year-olds are now being analyzed. At the age-11 assessment, the EP group was found to have significantly impaired lung function (J Pediatr. 2012 Oct;161[4]:595-601.e2), high risk for neurodevelopmental disability (Pediatrics. 2009 Aug;124[2]:3249-57), a high rate of learning impairments, and an 18-fold increased risk of poor academic attainment compared to their matched peers (Arch Dis Child Fetal Neonatal Ed. 2009 Jul;94[4]:F283-9).

EPICure is funded by the Medical Research Council. Dr. Beckmann reported having no financial conflicts of interest.

[email protected]

Clinical question: What are the factors that promote education in delivering high-value, cost-conscious care?

Background: Healthcare costs are increasing, with most recent numbers showing U.S. expenditures on healthcare of more than $3 trillion, almost 18% of the gross domestic product. High-value care focuses on understanding the benefits, risks, and costs of care and promoting interventions that add value.

Study design: Systematic review.

Setting: Physicians, resident physicians, and medical students in North America, Asia, and Oceania.

Synopsis: Seventy-nine articles were included in the analysis, with 14 being RCTs. Most of the studies were conducted in North America (78.5%) and used a pre-post interventional design (58.2%). Practicing physicians (36.7%) made up the majority of participants in the study, with residents (15.2%) and medical students (6.3%) in smaller numbers. Analysis of the studies identified three factors for successful learning:

• effective transmission of knowledge about prices of services and general health economics, scientific evidence, and patient preferences;
• facilitation of reflective practice through feedback and/or stimulating reflection; and
• creation of a supportive environment.

Bottom line: The most-effective interventions in educating physicians, resident physicians, and medical students on high-value, cost-conscious care are effective transmission of knowledge, reflective practice, and supportive environment.

Citation: Stammen LA, Stalmeijer RE, Paternotte E, et al. Training physicians to provide high-value, cost-conscious care: a systematic review. JAMA. 2015;314(22):2384-2400.

Clinical question: What are the factors that promote education in delivering high-value, cost-conscious care?

Background: Healthcare costs are increasing, with most recent numbers showing U.S. expenditures on healthcare of more than $3 trillion, almost 18% of the gross domestic product. High-value care focuses on understanding the benefits, risks, and costs of care and promoting interventions that add value.

Study design: Systematic review.

Setting: Physicians, resident physicians, and medical students in North America, Asia, and Oceania.

Synopsis: Seventy-nine articles were included in the analysis, with 14 being RCTs. Most of the studies were conducted in North America (78.5%) and used a pre-post interventional design (58.2%). Practicing physicians (36.7%) made up the majority of participants in the study, with residents (15.2%) and medical students (6.3%) in smaller numbers. Analysis of the studies identified three factors for successful learning:

• effective transmission of knowledge about prices of services and general health economics, scientific evidence, and patient preferences;
• facilitation of reflective practice through feedback and/or stimulating reflection; and
• creation of a supportive environment.

Bottom line: The most-effective interventions in educating physicians, resident physicians, and medical students on high-value, cost-conscious care are effective transmission of knowledge, reflective practice, and supportive environment.

Citation: Stammen LA, Stalmeijer RE, Paternotte E, et al. Training physicians to provide high-value, cost-conscious care: a systematic review. JAMA. 2015;314(22):2384-2400.

Clinical question: What are the factors that promote education in delivering high-value, cost-conscious care?

Background: Healthcare costs are increasing, with most recent numbers showing U.S. expenditures on healthcare of more than $3 trillion, almost 18% of the gross domestic product. High-value care focuses on understanding the benefits, risks, and costs of care and promoting interventions that add value.

Study design: Systematic review.

Setting: Physicians, resident physicians, and medical students in North America, Asia, and Oceania.

Synopsis: Seventy-nine articles were included in the analysis, with 14 being RCTs. Most of the studies were conducted in North America (78.5%) and used a pre-post interventional design (58.2%). Practicing physicians (36.7%) made up the majority of participants in the study, with residents (15.2%) and medical students (6.3%) in smaller numbers. Analysis of the studies identified three factors for successful learning:

• effective transmission of knowledge about prices of services and general health economics, scientific evidence, and patient preferences;
• facilitation of reflective practice through feedback and/or stimulating reflection; and
• creation of a supportive environment.

Bottom line: The most-effective interventions in educating physicians, resident physicians, and medical students on high-value, cost-conscious care are effective transmission of knowledge, reflective practice, and supportive environment.

Citation: Stammen LA, Stalmeijer RE, Paternotte E, et al. Training physicians to provide high-value, cost-conscious care: a systematic review. JAMA. 2015;314(22):2384-2400.